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Abstract 
Cancer is one of the leading causes of death in the world. Over the past several decades, the 
development of engineered nanosystems for targeted drug delivery have received great 
attention thanks to their possibility to overcome the limitations of classical cancer 
chemotherapy including poor solubility, targeting incapability, nonspecific action and, 
consequently, systemic toxicity.  
In this contest, four different models of nanocarriers have been analysed and compared for 
their capacity to target tumour tissue and to release the therapeutic agent in a controlled way: 
INU-EDA-P,C-DOXO; PHEA-EDA-P,C-DOXO; PVP-siRNA and RGO-siRNA.  
Inulin and PHEA were conjugated to the antineoplastic drug doxorubicin through a 
citraconylamide bridge used as a pH sensitive spacer and their different action in normal and 
tumour cells was compared by viability assay, fluorescence microscopy and flow cytometric 
analysis. The data revealed a higher effect against the cancer cells probably due to the higher 
capability to enter the cancer cells respect to the healthy ones, but also due to a partial drug 
release in tumour microenvironment, that presents a lower pH (6.5) respect to normal tissue 
(7.4). Because of the better efficiency of PHEA-EDA-P,C-DOXO, its preferential uptake 
into tumour cells was further demonstrated through co-culture experiments. Moreover, 
cellular internalization mechanism studies suggested a model in which the polymer would 
enter the cells through a caveolae-mediated endocytosis and would be steered toward 
lysosomal compartment where the drug would be released and become free to go into the 
nucleus. 
On the other hand, siRNA delivery was investigated comparing other two kind of 
nanosystems: PVP and Graphene nano-complexes conjugated with siRNA against Egr-1 (a 
transcription factor involved in the progress of the tumour) and Bcl-2 (a protein related with 
the apoptotic pathway in cancer cells). They are very different complexes, each with specific 
properties that would influence differently their ability as siRNA delivery system. 
Data relative to PVP nanogel showed it as a good candidate for siRNA delivery because it 
binds siRNA without any functional alteration or degradation. Moreover, the addition of a 
glutathione sensitive linker permitted a higher amount of siRNA released through a 
controlled way. Even graphene nanosystems have displayed good features as nanocarriers 
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thanks to their biocompatibility and their ability to be internalized by cells. Furthermore, 
their bidimensional nature would permit to conjugate a large amount of oligonucleotides. 
All the complexes analysed showed specific features that make them good candidates for 
drug or siRNA delivery. The choice of the best nanosystem is depending on the target site 
and on the therapeutic agent conjugated. PHEA nanopolymers present better characteristics 
for doxorubicin delivery compared with those of Inulin. On the other hand, the hydrogel 
nature of PVP and the bidimensional structure of graphene can minimize the typical 
degradation problems of the oligonucleotides and, therefore, offer the best conditions for 
siRNA delivery.   
Moreover, the possibility to release biological molecules in controlled way (mediated by pH 
or Glutathione) and to recognize the specific tumour target allow to overcome the typical 
limits of the classic cancer therapy.  
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Nanoscience and Nanotechnology 
Nanoscience represents one of the most interesting field of modern science, with a highly 
interdisciplinary character, indeed it develops by the mix of different doctrines like 
chemistry, biology, physics and engineering, taking advantage of their principles and of their 
processes. It is based on understanding and knowledge of the matter properties on 
nanometric scale (between 1 and 100 nm). The realization of materials, systems and 
apparatuses on this size scale determines the nanotechnology (Ahmad Gatoo et al., 2014).  
The term "nanotechnology" was first defined by Norio Taniguchi of the Tokyo Science 
University in 1974 (Taniguchi, 1974). In the 1980s, the idea of nanotechnology as 
deterministic, rather than stochastic, handling of individual atoms and molecules was 
conceptually explored in depth by Dr. K. Eric Drexler that called it Molecular 
Nanotechnology (MNT) (Drexler, 1986). It is a constantly evolving field that finds 
application in many productive sectors, in fact, it is widespread the use of nanoparticles for 
cosmetics, coating and paints, but also for high tech with the production of nano-hard disks 
or memory chips. One of the major applications concerns the biomedical environment 
(Nanomedicine) principally for tissue engineering (Van Vlierberghe et al., 2011) and drug 
delivery system (DDS) (Ranganathan et al., 2012; Tiwari, 2012). Nanosystems (1-100nm) 
can be design as vehicles for biological molecules like drugs capable of going inside cells 
with a size between 1 and 100 µm (Figure 1). The size comparison between all the cellular 
components and the nanoparticles (NPs) can give an idea of their potentiality especially for 
the cure of many diseases like tumours. Furthermore, their very small size confers them 
specific properties, because they are subjected to physical laws that are in the middle 
between classical and quantum physics (Papazoglou, 2007). 
Figure 1. Dimensional scale from nanoscopic to macroscopic. Cell presents a diameter 
between 1 and 100 µm, while nanoparticles between 1 and 100 nm.   
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The engineered nanomaterials can be synthetized by two different approaches that can be 
also used in complementary way (Figure 2):  
 Top down: it is a physical approach that consists on the reduction of macrostructures 
named bulk materials through procedures of incisions, grindings and cuttings 
(Nagavarma et al., 2012).   
 Bottom up: it is a chemical approach that brings to NPs production starting from 
atoms or molecule aggregates. This is the typical synthesis mechanism adopted in 
biomedical field because it permits a specific control of the process in order to obtain 
nanostructures with the desired properties.  
 
 
Figure 2. Representation of Top-down and Bottom-up processes for the nanomaterials 
synthesis. 
 
Nanoparticles  
Nanoparticles (NPs) are dispersion solution of atomic aggregates or solid particles with a 
size between 1 and 300 nm. They can be constituted by different materials and can assume 
both irregular of regular shapes like cube, sphere, rod or plate (Salata, 2004).  
The possibility to engineer their surface permits multifunctional applications especially in 
clinical environment for diagnosis and therapies (Siddiqui et al., 2015; Haun et al., 2010; 
Srikanth et al., 2012), but also for  bio-localization studies (bioimaging) through conjugation 
with fluorescence probes (Xing et al., 2014).  
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Depending on the nanoparticles’ nature, it is possible to classify them in inorganic or organic 
NPs (Jesus and Grazu, 2012) (Figure 3). 
 
Figure 3. Schematic representation of inorganic and organic nanoparticles.  
 
Inorganic nanoparticles 
Inorganic nanoparticles play a fundamental role in modern materials science due to their 
unique physical characteristics like size-dependent optical, magnetic, electronic, and 
catalytic properties. They can be easily and cheaply synthesized and mass produced, and for 
this reason, they can also be more readily used for many applications. These inorganic 
nanoparticles include iron oxides, gold, silver, silica, quantum dots (QDs) and second 
harmonic generation (SHG) particles (Ladj et al., 2013).  The Quantum dot is a crystal of 
semiconductor material whose diameter is about several nanometers (from 1 to 100 nm). Its 
optical properties vary depending of its size so that it can emit different fluorescence 
(Ryman-Rasmussen et al., 2006). Indeed, when the metallic nanoparticles (MNPs) are lit up 
with a beam of light, the oscillating electric field induces the movement of the electrons with 
consequent special optical phenomena (Siddiqui et al., 2015). 
The more used  metals for the development of NPs are those noble like gold, silver or copper 
with a diameter around 100 nm (Okuzaki et al., 2013). In recent years, gold nanoparticles 
(AuNPs) have been object of interest for cancer research because of their easy synthesis and 
surface modification, and tunable optical properties (they show strong surface plasmon 
resonance bands in the visible region) as well as excellent biocompatibility with the 
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biological systems (Huang et El-Sayed, 2010). On the other hand, silver NPs can be 
exploited for their antibacterial and antifungal properties (Prucek et al., 2011), while 
magnetic NPs are largely used for applications in site specific treatments such as targeted 
drug delivery, localized heating of cancerous cells (hyperthermia), and magnetic resonance 
imaging (MRI) contrast enhancement (Frey NA et al., 2009). 
Organic nanoparticles 
In the last years, many researchers have focused their studies on the possible use of organic 
nanoparticles (ONPs) in different sectors especially in the biomedical ones. The organic 
nature of these systems, indeed, highly  reduces their toxicity and therefore side effects. 
There are different types of ONPs depending on heir composition and structure like 
liposomes and micelles, dendrimers, polymeric NPs and nanogels.  
Liposomes and micelles 
Liposomes are vesicles constituted by self-assembled phospholipid bilayer that delimits an 
aqueous core in which can be encapsulated hydrophilic molecules like some drugs (Figure 
4, Panel A). They can transport also hydrophobic molecules in the lipid bilayer (Conniot et 
al., 2014). For this reason, they are largely employed in drug delivery system because they 
can fuse with the plasmatic membrane and release the drug inside the cell (Catalina et Pérez, 
2005). Their chemical-physical properties can be accurately modified by mixing different 
lipid molecules and therefore changing the superficial charge, the size and functionalization. 
Even if they have a good distribution in the organism, they present some advantages like the 
possibility to change lipid components with High or Low-density lipoprotein (HDL and LDL 
respectively) and thus modify their size and composition, but also their accumulation into 
the tissues (De et al., 2008). Micelles, instead, are characterized by a single lipid layer that 
defines a spherical structure with a hydrophobic core, fundamental for the transport of 
lipophilic molecule like many antitumor drugs (Prabhu et al., 2015) (Figure 4, Panel B).  
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Dendrimers 
Dendrimers are nanovectors with a spherical shape constituted by polymeric 
macromolecules that are capable of self- assembling. They present three different parts: a 
central hydrophobic core, ramification units and hydrophilic functional groups at the 
external side that can be conjugated with specific molecules for a targeting activity (Figure 
4, Panel B). Their synthesis is based on a polymerization process of the ramification units 
from the surface to the core (convergent synthesis) or vice versa (divergent synthesis) and it 
can be patterned to control the drug release (Nanjwade et al., 2009). 
 
Figure 4. Representation of Micelles and liposomes (Panel A) and of Dendrimers (Panel B): 
Polymeric structures constituted by monomeric units (ABn).  
 
Polymeric nanoparticles 
Polymeric nanoparticles (PNPs) are solid colloidal systems formed by a polymeric matrix 
with a range size from 10 to 500 nm. Depending on the synthesis process, the resulting 
structure can be nanospheres (the drug is dispersed in the matrix) or nanocapsules (the drug 
is confined in an aqueous core surrounded by a polymeric membrane) (Figure 5, Panel A). 
This particular structure protects drugs from the enzymatic and hydrolytic degradation, so 
that they are optimal candidate as drug delivery systems. In details, therapeutic agent can be 
dissolved, trapped, encapsulated or absorbed by the polymeric matrix and therefore can be 
released with different mechanisms like desorption, diffusion or erosion. The natural mostly 
used polymers for the PNPs synthesis are Chitosan, Gelatin, Sodium Alginate and Albumin. 
Instead, the synthetic ones are Polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), 
Polyvinylpyrrolidone (PVP), Polyethylene glycol (PEG), Poly(methyl acrylate) (PMA), 
Poly(acrylic acid) (PAA) and Polyacrylamide. In particular, PLA and PLGA are amply used 
for drug delivery system thanks to their biocompatibility and their ability to slowly dissolve 
B A
A
A 
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in solution. For this reason, they have been approved by Food and Drug Administration 
(FDA) for the parenteral injection (Alexis et al., 2009). Indeed, PNPs present higher stability 
respect to other NPs, and they can be functionalized for a controlled drug release and to have 
a prolonged action; finally, they can be administered with a multitude of methods. 
 
 
Figure 5. Representation of: polymeric nanoparticles [nanospere and nanocapsule] (Panel 
A) and nanogel (Panel B).   
 
Nanogels 
Nanogels (NGs) are hydrogels of nanometric size, constituted by polymer chains that form 
a network able to absorb and retain high quantity of aqueous solution (swelling capacity) 
(Kabanov et al., 2009) (Figure 5, Panel B). The hydration capacity is due to basic or acid 
groups of the polymers that facilitate the retention of water molecules in the inner regions 
(Dispenza et al., 2012). Their size (form 10 to 300 nm) and their shape are determined by 
the equilibrium between the osmotic pressure generated by the aqueous component and the 
elastic force of the polymer (Alexander et al., 2009). Nanogels can be classified in function 
of their chemical composition (synthetic, natural or hybrid NGs) or in function of their 
surface charge (neutral, anionic or cationic NGs) (Miyata et al., 2002).  
Thanks to their characteristics, they are largely used as vectors for small molecules like 
fluorescence probes (bioimaging) or drugs (drug delivery system) (Yamane et al., 2008). 
Indeed, they present many vantages like stability, a large flexible surface for the conjugation 
with a big amount of cargo that is protected in an aqueous environment. The biological 
A
A
B
A
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molecules can be loaded through spontaneous interactions (like hydrophobic, electrostatic 
or van der Waals interactions) with the polymer. Furthermore, it is possible also a specific 
binding of proteins, nucleic acids, drugs or other molecules, with the functional groups (like 
-OH, -CONH-, -CONH2) on the NGs surface (Yun, et al., 2012). In this way, it is possible 
a specific cargo release induced by ionic force, pH, temperature or chemical stimuli (Gibas 
et al., 2010; Miyata et al., 2002). 
Natural polymers like alginic acid, chitosan, collagen, fibrin and hyaluronic acid (HA) or 
synthetic polymers like polyacrylic acid (PAA), polyvinylpyrrolidone (PVP), polyvinyl 
alcohol (PVA) and polypeptides can be used for the synthesis process. 
 
 
Drug Delivery system 
Classical pharmacological treatments (parenteral, oral, cutaneous or topic) for diseases and, 
in particular, the cancer chemotherapy can induce side effects because of their nonspecific 
action: indeed, they act both on normal and tumour cells. Furthermore, the drug dilution in 
the bodily fluids limits its absorption in the target tissue so that it is necessary to administer 
substantial doses to have a high local concentration. Moreover, Conventional Drug 
Administration Systems (CDASs) present pharmacological-kinetic limitations: the therapy 
requires periodic doses of therapeutic agent that, in a short time, overpasses the “therapeutic 
band” reaching very high levels and consequently resulting toxic; soon after, instead, its 
concentration decreases at a level in which it is ineffective (Figure 6, Panel A) (Leroux et 
al., 1996; Audumbar and Ritesh, 2015).  In such cases, a method of continuous 
administration of therapeutic agent is desirable in order to maintain fixed plasma levels as it 
happens using nanoparticles for Drug delivery system. Therefore, the use of nanoparticles 
for drug delivery system, can resolve all these problems (Ranganathan et al., 2012; Tiwari, 
2012). Figure 6, panel B, shows the drug trend when it is administered through a NPs system: 
the drug level, after only one dose, is maintained constant over time and then decreases 
slowly.    
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Figure 6. Drug levels in the blood with a) Traditional drug dose systems and b) Drug 
delivery system. 
 
The use of nanosystems permits a controlled release of the conjugated drug, depending on 
physiological conditions of the targeted site (site specific-targeting) and a modulation during 
the release time (temporal modulation), in function of the physical properties of the 
microenvironment (Swami et al., 2012). 
The Drug Delivery System develops from the coordination of three components (Figure 7):  
 Cargo i.e. drug 
 Targeting molecule 
 Nanocarrier  
In a unique system, these components permit to carry and then release the drug in a specific 
tissue and in a controlled way and, at the same time, to increase the drug therapeutic effect. 
 
 
Figure 7. Representation of targeted delivery mediated by a nanoparticle.  
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Project of nanoparticles 
Nanoparticles have to be synthetized, engineered and optimized in order to raise the 
circulating half-life and to obtain a site-specific release of drugs at therapeutically optimal 
levels and dose regimes. The composition, size, shape, surface properties, biocompatibility 
and degradation profile should be carefully considered for the optimal design of the NPs for 
therapeutic therapy (Figure 8) (Tianmeng Sun et al., 2014).   
 
 
Figure 8. Schematic representation of the principal characteristics to project the NPs. 
 
Size and shape 
The size is a fundamental characteristic of the nanoparticles especially for their long 
circulation, biodistribution and clearance. Generally, their size is between 1-100 nm to 
permit a longer circulation half-life in vivo and a reduced hepatic filtration. Additionally, 
their small size consents a higher cellular internalization compared with microparticles, as 
described by Desai et al.. They performed uptake studies in a Caco-2 cell line by comparing 
17 
 
100 nm nanoparticles with 1 µm and 10 µm microparticles: NPs had a 2.5 and 6-fold higher 
uptake level than microparticles (Desai et al., 1997). In particular, very small NPs (size 
smaller than 10 nm) can easily cross the blood vessels and be cleared by kidneys, while 
bigger nanoparticles can be intercepted by cells of the mononuclear phagocyte system 
(MPS). 
NPs can be also adopted for the therapy of some brain diseases such as Parkinson, Alzheimer 
or glioma. Indeed, they can across the blood brain barrier (BBB) through the opening of tight 
junctions (TJ) if treated with a hyperosmotic mannitol solution (Kroll et al., 1998).  Finally, 
their size can also concern the drug release because the smallest particles present a larger 
surface area so that the majority of the conjugated drug would be at or close to the particle 
surface, facilitating a fast drug release.  
The shape of nanoparticles (sphere, cube, rod, plate) plays, also, a key role in uptake and 
drug release processes. Many studies have demonstrated that, for example, spherical 
particles are good candidates for drug delivery because they are internalized with higher 
likelihood and faster than rod-shaped NPs (Chithrani et al., 2006). On the other hand, even 
the rod NPs orientation to the cellular membrane is important for the cellular uptake, indeed 
this kind of particles have a higher probability of internalization when their major axis is 
perpendicular to the cell membrane (Champion and Mitragotri, 2006). Shape can also 
influence their tissue-specific accumulation: for example, cylindrical and regular spherical 
NPs gather in the liver; discoidal-shaped NPs in the heart and irregular spherical NPs in the 
spleen (Park et al., 2009; Devarajan et al., 2010). 
Surface proprieties  
The hydrophobic character of NPs can shorten their circulation time in vivo because of the 
opsonization process in which small molecules, called opsonins, adhere to NPs surface 
facilitating their phagocytosis by the cells of the immune system. In this contest, even the 
NPs surface charge is implicated in their uptake by the MPS cells. Indeed, positively charged 
NPs induce higher complement activation compared to negatively and neutrally charged 
NPs. The charge is important also to determinate the NPs zeta potential and therefore the 
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aggregation state in solution: nanoparticles with a zeta potential above (+/-) 30 mV have 
been shown to be stable in suspension and prevent the aggregation process.  
In order to prolong the circulation time of the particles it is possible directly  synthetize them 
from block polymers presenting both hydrophobic and hydrophilic fragments (Harris 2001, 
Adams 2003) or to coat them with hydrophilic protective layer like polyethylene glycol 
(PEG) (Mohanraj 2006, Kamaly 2012, Xia 2012). The PEG conformation on the 
nanoparticles surface is fundamental in repelling opsonins, for example a brush-like 
configuration of PEG limits phagocytosis and complement activation, while, a mushroom-
like arrangement favours both processes (Yang 2010). On the other hand, the presence of 
PEG shell on the NPs can interfere with the target cells  interaction and prevent the 
endosomal escape, as demonstrated by many studies in which it has been compared the effect 
of the same nanoparticles PEGylated or not (Du 1997). For these reasons, in the last years, 
many studies have focused on the development of new strategies to increase the circulation 
life of NPs, including the use of synthetic or natural polymers, or the coating with biomimetic 
molecules, or red blood cell (RBC) membranes to evade the immune response cascade 
(Sambruy 2001). 
The coating process can also increase the NPs uptake: Chitosan, for example, can help to 
disrupt the integrity of intracellular TJs involved in paracellular transport, thus facilitating 
the delivery of higher amount of nanocarriers to the targeted site (Luk2014).   
 
Nanoparticles targeting  
The physicochemical characteristic of nanoparticles like size, shape, surface charge, surface 
proprieties and their possible conjugation with specific biological molecules, can improve 
the delivery of drugs to the target tissue through to two different ways: passive and active 
targeting (Figure 9 and 10). 
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Passive targeting  
In the passive targeting, the localization of the particle depends only on morphological, 
chemical and physical features of the nanoparticle and on the anatomical and physiological 
characteristics of the target site.  
Normally, small molecules, including NPs, are retained in the bloodstream because they 
cannot cross the tight junctions between endothelial cells of normal vascular linings. By 
contrast, tumour tissue needs of extensive vascularization to receive sufficient supplies of 
nutrients and oxygen; therefore, the rapid growth lends itself to a leaky and defective 
architecture. Differently from healthy tissue, tumour microvasculature is characterized by 
abnormal branching and enlarged interendothelial gaps due to damage of TJs between 
endothelial cells and a disrupted basement membrane (Figure 9) (Martin, 2014). In this 
contest, small particles, with opportune size, can easily cross through the large gaps and 
extravasate from the surrounding vessels to the malignant tissue by means of a passive 
targeting mechanism named EPR (Enhanced Permeation and Retention) effect. Therefore, 
this phenomenon depends not only on the NPs size but also on the gaps size that can be 
dissimilar between several tumours and even between different parts of the same tumour 
(100-800 nm).  
In the malignant tissue, it is evident also a dysfunction of the lymphatic system that, 
sometimes, can be even totally absent inducing the NPs accumulation. In this way, the 
concentration of the drug released from vectors in tumour microenvironment can reach 
levels from 10 to 100 times higher than those obtained from the administration of free drug 
through the classical pharmacological treatments. 
In 1986, Matsumara and Maeda have described, for the first time, the ERP Effect. They have 
carried out localization experiments by comparing two complexes of different sizes: a 
polymer conjugated with an anticancer molecule named poly(Styrene-co-Malei Acid)-Neo 
Carrzino Stain (SMANCS) (16 kDa) and a system formed by its non-covalent bind with 
labelled Albumin (SMANCS-Albumin) (80 kDa). In particular, they have noted that the 
proteins larger than 30 kDa had preferentially accumulated into tumour interstitium and had 
lingered there for a prolonged period of time (Matsumura and Maeda, 1986).  
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Therefore, nanoparticle’s size plays a key role in EPR-based tumour targeting. On one hand, 
the NPs need to be not too much big: different studies have shown that particles with a 
diameter smaller than 200 nm are more effective than the larger ones that could be more 
rapidly cleared from the bloodstream by the spleen (Aruna et al., 2013). On the other hand, 
the NPs need to be not too much small because they would travel back to the blood vessels: 
nanoparticles with size range of 30-200 nm present an excellent retention by the tissue 
resistance that shifts the equilibrium toward the extravasation and therefore induces their 
accumulation in the tumour site.  
The passive targeting efficiency is influenced also by the NPs shape associated with tumour 
interstitial pressure in the malignant interstitium that takes position against the extravasation 
process (Ferrari, 2005). For example, nanosystems with a spherical shape tend to follow a 
laminar flow pattern so that, when they are in close contact with the vessel wall, they can 
cross the gaps and go into the tumour microenvironment. Instead, rod or bar-shaped 
nanoparticles are hydro-dynamically more unstable and so they have more difficulty to 
follow a laminar flow pattern and to linger into the bloodstream (Decuzzi et al., 2005) 
EPR effect is due to the high permeability of tumour vasculature, therefore many vascular 
mediators such as Nitric Oxide (NO), Carbon Monoxide (CO), Vascular Endothelial Growth 
Factor (VEGF), can increase this phenomenon. NO is a signalling messenger involved in 
different pathways and produced by NO synthase that is more expressed in cancer cells than 
in healthy ones, suggesting that there is a higher NO production in tumours. Indeed, NO is 
probably involved in their growth as demonstrated by NOS knockout mice experiments: by 
inhibiting the NO synthesis, there is an intense reduction of the extravasation process, 
demonstrating its involvement in EPR effect (Kisley et al., 2002).  In cancer 
microenvironment, alsoCO induces angiogenesis thanks to its action as vasodilator: 
experiments in which the production of CO is induced by a CO donor showed an increase 
of vascular permeability and blood flow thus determining an higher EPR effect. 
Although often EPR effect promotes nanoparticles targeting in tumour site and it is widely 
exploited for cancer therapy, passive targeting efficiency can be rather limited because of 
the nature of the tumour. For example, small tumour or metastatic lesion does not present 
strong and diffused angiogenesis, so that vessels are not evenly distributed and size of gaps 
can be different in several part of the same malignant site (Aruna et al., 2013). Hence, it is 
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necessary to improve specific targeting by conjugating specific molecules for an active 
targeting. 
 
Figure 9. Passive targeting: EPR Effect. 
 
Active targeting  
Tumour cells overexpress many characteristic molecules into their membrane that can bind 
antigens like growth factors and induce various tumorigenic pathways such as angiogenesis 
or growth metabolic ones. Active targeting, named also ligand-mediated targeting, is based 
on this feature: nanoparticles can be conjugated to a targeting moiety that purposely bind to 
the surface of a definite type of cells, like tumour cells. Therefore, active and passive 
targeting can be independent or, sometimes, combined in order to improve the nanoparticles 
efficiency.  
The active targeting can be formulated not only to directly recognise tumour cell, but also 
other cellular types involved in cancer progression. An example is the active vascular 
targeting (Neri et al., 2005) in which the molecules conjugated to NPs recognise 
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angiogenetic endothelial cell surface receptors including fibronectin (extradomain B), 
integrins, annexin A1 and grow factors or their receptors like VEGFs and VEGFR. Once 
internalized, the nanosystems can release specific drugs or biological molecules able to 
induce apoptotic events in the endothelial cells that, in this way, cannot supply oxygen and 
nutrients to tumour: in this manner cancer mass is eradicated. 
Beyond the function in the specific identification, the active targeting increases also cellular 
uptake as result of receptor-mediated endocytosis when the NPs are in tumour 
microenvironment. In this contest, density and orientation of ligands and their affinity for 
the substrate, result to be fundamental, because the multiple interactions of the NPs with the 
target cell membrane determine the clustering of receptors and so the improvement of the 
endocytosis. By contrast, high ligand density can facilitate the macrophage phagocytosis and 
consequently can sequester them to tumour cells; therefore, the identification of the antigen 
optimal concentration needs to be well investigated.  
It is fundamental to keep unchanged the efficiency and physicochemical properties like size 
and shape of nanomaterials during the conjugation process, because the NPs can be modified 
by density, orientation or charge of ligands (Bertrand et al., 2014). In particular, the 
attachment strategies depend on NPs’ nature: usually the ligand is linked by a covalent bond, 
but, in some cases, it is preferable a physical adsorption like it is for liposomes in which the 
ligands require of a bulkier hydrophobic anchor to insert them into the lipid bilayer in order 
to increase their stability, especially in vivo. Moreover, some inorganic polymers need the 
interposition of functional groups like NH2 or OH to link targeting ligands, dye molecules 
for localization studies or drugs. 
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Independently of conjugation approaches used, nanoparticles can be functionalized using 
targeting ligands of different nature like aptamers, small molecules, peptides, antibodies, 
carbohydrates or glycoproteins in function of the characteristic of the target cells (Figure 
10).  
 
 
Figure 10. Ligands for a nanoparticles’ active targeting.   
 
Aptamers 
Aptamers (Apts) are small single-stranded DNA or RNA oligonucleotides (20-80 
nucleotides) that can fold into unique tertiary configuration capable of binding proteins, 
phospholipids, acid nucleic or carbohydrates expressed by target cells. When they are 
conjugated to NPs, they are optimal candidates for tumour targeting, thanks to many features 
like very low immunogenicity and stability and capacity to tolerate small variations of 
temperature or pH. Moreover, a specific chemical process named “Systemic evolution of 
ligands by exponential enrichment” (SELEX) permits to select and amplify the aptamers 
with higher binding affinity for the target molecules, starting from a random library of single-
stranded DNA or RNA (Daniels et al., 2003). Furthermore, their functionalization with 
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molecules such as PEG or cholesterol improves half-life of aptamer-NPs in bloodstream and 
delay their clearance by the kidneys (Nimjee et al., 2005). 
It has been identified even an Apts role as pharmaceutical agents because some of them can 
inhibit proteins involved in pathological pathways (i.e. the Pegaptanib Sodium aptamer 
recognise VEGF protein) (Bates et al., 2009). However, because of their expensive cost of 
production, it is preferable employ Apts only as targeting agents. 
Small molecules  
Organic small molecules, with a molecular weight less than 500 Da, can be used for active 
targeting because they present high stability, chemical management, low cost production and 
especially a high binding affinity for different substrates of interest. The most famous 
example is Folic Acid (FA), named also Vitamin B9: it is involved in many metabolic 
pathways like cellular proliferation and DNA or RNA synthesis and it can link, with very 
high specificity and affinity, to its receptor (Folate Receptor-FR) that is over-expressed in 
the majority of human tumours (brain, colon, ovarian, breast, renal and lung cancers). Some 
studies have suggested a higher uptake of FA-NPs compared with NPs alone (Zhang et al., 
2015) and a higher cytotoxic effect, when the nanosystem is conjugated also with an 
anticancer drug. Another small molecule abundantly adopted for active targeting, is TPP 
(triphenyl-phosphonium) that is a positively charged molecule able to cross the mitochondria 
membrane and so it accumulates inside this cellular compartment (Smith et al., 2003). 
Furthermore, TPP can partially confer positive charge on NPs (zeta-potentia more than 
+22mV) that, in this way, can escape the endosomal compartment and accumulate in 
mitochondria more than NPs alone (Marrache et al., 2012). 
Peptides 
Peptides are linear or cyclic sequence of amino acids (not more than 50 residues) that can 
fold into three-dimensional structures acquiring high stability and resistance against the 
immune system, so that they can be used as targeting moieties unlike proteins.  
cRGD (cyclic RGD), a member of peptide family RGD (arginine- glycine- aspartic acid),  is 
largely studied because of its capacity to recognise and bind the αVβ3 integrin receptors, 
overexpressed on both tumour and angiogenetic endothelial cells. It is partially expressed 
also on normal or inflamed tissues even though at low levels and some data has demonstrated 
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that cyclic form presents 10-fold higher anti-cancer activity (Colombo et al., 2002). 
Furthermore, cRGD can upregulate VEGF signal through its receptor VEGFR-2 that is 
typically associated to αVβ3; indeed by inhibiting the αVβ3 binding site, there is a reduction 
of VEGF signalling, resulting in an anti-angiogenic mechanism (Ruoslahti et al., 2002).  
In this contest, the use of cRGD conjugated with NPs induces two advantages: it can improve 
specific targeting but it can also, indirectly, downregulate VEGF pathway and induce an 
anti-angiogenetic effect (Blanco et al., 2010). Several types of nanosystems were synthetized 
using RGD as targeting molecule and a variety of moieties as therapeutic agents among 
which drugs like doxorubicin or paclitaxel, but also siRNA to block mRNA involved in 
tumour growth pathways. 
Dong Han and colleagues carried out studies using a system composed by RGD peptide-
labelled chitosan nanoparticle (RGD-CH-NP) as a tumour targeted system for siRNA 
delivery (siRNA/RGD-CH-NP). They showed that the presence of cyclic peptide 
significantly increases selective intratumoral delivery in orthotopic animal models of ovarian 
cancer that overexpress integrin αVβ3 (Han et al., 2010). 
 
Antibodies and their fragments 
The most important class of targeting moieties used is certainly composed by monoclonal 
antibodies (mAb), thanks to their very high specificity and capacity to strongly bind the 
corresponding (complementary) antigen expressed by targeted cells (Figure 11). Because of 
mAb role in the immune response, they confer high immunogenicity to the NPs after 
conjugation; therefore, the use of engineered antibodies in order to obtain Ab-fragments that 
can escape the immune system is largely diffused. Some of them, like single-chain variable 
fragments (scFv), present only the Fab region able to recognize specific antigen (the Fc 
portion confers the immunogenic propriety). In particular, scFv are fusion proteins 
constituted by the variable regions of both heavy and light chains of the Ab linked with a 
short peptide of about 15 amino acids (Chen et al., 2010).  
MCC-465 and STG-53 are two examples of Ab-fragment-targeted NPs: the first one shows 
excellent results in preclinical studies in doxorubicin delivery for stomach tumour cells (Jain 
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et al., 2010); while the second one is able to bind transferrin receptors (Tf-R) on cancer cell 
membrane and to release into the cytoplasm a p53 inhibitor (Nemunaitis et al., 2008).  
Thanks to their properties, since the 1980s, more than 30 different types of mAb and their 
derivatives have been accepted for clinical use like cetuximab, rituximab, bevacizumab or 
trastuzumab. 
 
Figure 11. Active targeting antibody-mediated (submitted data). 
 
Carbohydrates and Glycoproteins 
Carbohydrates (CHs) are very important mediators of cell-cell interactions so that they are 
involved in many mechanisms such as cellular differentiation, cell signalling regulation and 
immune response. Even if they can bind lectins ubiquitously expressed, many studies have 
reported the presence in tumour cells of proteins similar in size and sugar-binding specificity 
to the lectins of the normal cells. Therefore, carbohydrates can be used as targeting ligands 
(Lotan et al., 1988). Different kinds of CHs can be involved in nanoparticles’ active 
targeting. For example, galactosamine binds specific membrane receptors into primary and 
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metastatic liver cancer cells. In this way, if conjugated to NPs, galactosamine permits their 
uptake via Receptor-mediated endocytosis only in tumour cells (Seymour et al., 2002). 
Beyond galactose, it has also been documented an active targeting by exploiting other 
carbohydrates moieties like mannose or glucose and their derivatives.  Nevertheless, CHs 
are not good targeting ligands because of their difficult synthesis and their labile glycosidic 
linkages that can be easily degraded by enzymes.  
On the other hand, glycoproteins like Lactoferrin (Lf) and Transferrin (Tf) are widely 
employed for this purpose and in particular, Lf- NPs have higher targeting efficiency for 
tumour cells than Tf-NPs (Choe et al., 1998).  
An important limit of the use of classical chemotherapeutic agents is the transport across the 
blood brain barrier (BBB) to act against neural cells for neural pathologies like Alzheimer, 
Parkinson or glioma. In this contest, both Lactoferrin and Transferrin can be conjugated to 
nanosystems to act in a complementary way. In depth, since many transporters, like the 
transferrin receptor, are expressed at the BBB, it is possible to use them for active targeting, 
so that Tf-NPs would cross the barrier and reach the target site in the brain. Once there, NPs 
functionalized also with Lf can recognise, for example, glioma cells that over-express Lf 
receptors as reported by two very similar studies about glioma treatment with Lf- liposomes 
(Pang et al., 2010; Chen et al., 2011). 
 
Cellular uptake 
Once arrived in the target site, nanosystems must first cross the cell plasma membrane 
through endocytosis, an energy-depending internalization process. This mechanism can be 
induced by a specific highly selective interaction between the targeting molecules associated 
to the NPs and their receptors on the membrane or by an unselective binding based on 
hydrophobic or electrostatic interactions. In this contest, size, shape and surface properties 
of NPs play a key role determining the specific internalization pathway (Mao et al., 2013) 
(Figure 12): 
 Clathrin-mediated endocytosis [receptor-mediated endocytosis (RME)]: the 
interaction between cellular receptor and its ligand on the NPs, induces the inward 
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budding of plasma membrane vesicles containing both receptor and ligand and 
coated by specific cellular proteins named clathrins. 
 Caveolae-mediated endocytosis: the membrane internalization occurs in 
correspondence of lipid rafts rich of cholesterol and caveolin that facilitate the 
vesicles formation.  
 Phagocytosis: cells internalize very big molecules (larger than 500 nm) or opsonized 
nanoparticles. This process is typical only of some cellular types like macrophages, 
monocytes and neutrophils.  
 Simple diffusion: molecules can cross the membrane without the vesicles formation.  
 
 
Figure 12. Pathway for the cellular internalization of different types of nanosystems.  
 
The endocytic mechanism is also influenced by the type and physiological condition of the 
cells as it has been demonstrated by many experiments comparing the uptake mechanism of 
the same nanosystem in different cellular lines (Chan et al., 2007). Moreover, the 
internalization process is a temperature-dependent mechanism: at 4°C, all the energy-
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mediated endocytic pathways are halted with the consequent reduction of the uptake level 
compared with the regular cultures performed at 37°C.  
When NPs are inside the cells, they can follow different ways: they can be transported along 
the endolysosomal network to other organelles or they can be exocytosed (Figure 13). Many 
cytoplasmic complexes are involved in this process, especially the cytoskeletal structures. It 
is also possible to direct the nanoparticles to a specific cellular compartment by conjugating 
them with a target sequence. For example, many studies have shown that a nuclear 
localization signal (NLS) peptide motif can be added to the NPs for a nuclear targeting (Mao 
et al., 2013). 
 
 
Figure 13. Intracellular transport of nanoparticles.  
 
Controlled drug release 
One of the most important aspects of drug delivery system is the possibility to control the 
conjugation process of therapeutic molecules and therefore also their release mechanism. In 
this contest, the nature and the physicochemical properties of both drug and nanosystem, but 
also the NPs synthesis process, play a key role, so that biological cargo can be adsorbed or 
covalently attached to the NPs surface or encapsulated inside (Liu et al., 2006). In this way, 
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the drugs are also protected from harsh environments like the highly acidic environment of 
the stomach, the blood stream rich of high levels of proteases or other enzymes, and even, 
at cellular level, the lysosomes that present a very low pH (Couvreur et al., 2013). All these 
factors determine an extended half-life of the drug and its higher concentration in the target 
site.  
There are many therapeutic agents used for tumour treatment that differ for chemical or 
physical properties (hydrophobicity or hydrophilicity and surface charge) (Sun et al., 2014). 
Hydrophobic drugs such as paclitaxel, methotrexate, cisplatin and doxorubicin, can 
aggregate in an aqueous solution like the extracellular environment or the bloodstream, 
inducing side effects such as embolisms and local toxicity (Owen et al., 2012). Their 
conjugation with vectors, especially micelles and polymeric NPs composed of hydrophobic 
or amphiphilic materials can prevent these complications. 
On the other hand, also the hydrophilic drugs increase their efficiency if conjugated with 
nanosystems. Indeed, the action of free hydrophilic drugs, including macromolecules such 
as proteins, peptides, and nucleic acids and many small molecules, can be impeded by the 
rapid MPS (mononuclear phagocyte system) clearance and kidney filtration (Ku et al., 
2014). Moreover, they are subjected to proteolytic and hydrolytic degradation and therefore 
they have a short half-life in bloodstream; additionally, they are unable to cross the 
hydrophobic lipid bilayer of cell membranes (Torchilin et al., 2003). The most important 
example is represented by siRNA, micro-RNA and DNA, with high charge density, highly 
used in gene therapy (Dispenza et al., 2014); even though they are not stable, their instability 
can be overtaken when they are transported by a nanosystem. Their conjugation occurs 
through electrostatic interactions between the nucleic acids (negatively charged) and 
nanocarriers (positively charged) (Woodrow et al., 2009) or through direct binding to 
functional groups on the NPs surface.  
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Independently of the drug nature, the drug controlled release from the nanosystems can be 
enclosed into two major categories: extended and stimuli-responsive release (Figure 14). 
 
Figure 14. Controlled drug release mediated by nanoparticles.  
Extended release  
Extended drug release permits to deliver drugs over a sustained period and to maintain 
constant their concentration in the plasma or target tissue by matching the rate of release and 
clearance of drugs (Robitzki et al., 2010). It is a model adopted especially for drugs rapidly 
metabolized and eliminated from the body and it can be realized through a diffusion or an 
erosion controlled mechanism (Figure 14). 
Diffusion-controlled release 
Diffusion-controlled release is typical of the nanosystems in which the drug is localized into 
their core delimited by an insoluble barrier usually made of an organic polymer. In this 
manner, the drug is protected from the aqueous environment and can be released by diffusion 
process at determined rate, depending by its physicochemical properties, such as porosity or 
thickness (Cheng et al., 2009). This kind of nanosystems are based on a water-insoluble 
matrix polymer such as poly(methyl methacrylate) (PMMA) and polyurethane (PUA) that 
are characterized by a two-phases release. In particular, there is an initial substantial 
detachment of therapeutic molecules from the NPs surface (“burst release”), and a second 
release of the other molecules from the core up to the surface thanks to their diffusion across 
the polymer matrix (Ma et al., 2011). 
32 
 
Erosion-controlled release  
Some nanocarriers are made of erodible or degradable polymers so that the drug is released 
by an erosion-controlled mechanism and therefore does not require additional clearance 
processes (Chen et al., 2006).  
Biodegradable polymers can be natural or synthetic. Poly (lactic acid) (PLA), poly(glycolic 
acid) (PGA), and poly(lactic-co-glycolic acid) (PLGA) are examples of synthetic polymers 
largely used for erosion controlled drug delivery. They can be easily metabolized by a 
hydrolytic process, through cleavage of the ester bond between lactic and glycolic acid so 
that they are subsequently eliminated as carbon dioxide and water (Göpferich et al., 1996).  
Polymer erosion can happen through a surface or bulk mechanism (Zuleger et al., 2001). 
The surface erosion occurs when the rate of erosion is faster than the rate of water permeation 
into the bulk of the polymer. On the other hand, bulk erosion happens when the water 
molecules can quickly penetrate into the polymer before that the erosion can take place and 
the chain scission occurs throughout the matrix. 
Stimuli-Responsive Release 
Some nanosystems can release the conjugated drugs in response to specific stimuli that can 
be broadly classified as either internal (i.e. pH variation, enzymes or redox state) or external 
(i.e. light, ultrasound, heating) (Figure 14). On one hand, chemical, biochemical, or physical 
stimuli can induce a modification of the structural composition or conformation of the 
nanocarriers with the consequent release of the drug entrapped within them (complexation 
approach). These modifications include isomerization, polymerization, decomposition, 
activation of supramolecular aggregation (Fleige et al., 2012). On the other hand, the release 
mechanism can involve the cleavage of a linker between the carrier and the drug 
(nanocarrier-conjugate approach). 
pH-responsive nanocarriers 
One of the most important features of the pathologic tissue (like those inflamed, infected, or 
cancerous) is the alteration of the pH values. The extracellular pH registered in solid tumours 
is more acid (pH 6.5–6.8) than those recorded in the healthy tissue (pH 7.4), probably 
because of the different vasculature and the consequent altered anaerobic conditions (Vaupel 
et al., 1989). The pH difference concerns also the intracellular compartments like endosomes 
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or lysosomes so that NPs following the classical endocytic pathway, can proceed through 
compartments with different pH (early endosome with pH about 5–6 and late lysosome with 
pH around 4–5) (Mura et al., 2013). In this way, a two-phase drug-release is possible: an initial 
delivery outside the cells so that free drug can diffuse through the plasmatic membrane, and 
a subsequent phase inside the cellular organelles.  
Several synthetic polymers have been developed as pH-sensitive nanocarriers, such as 
poly(acrylamide) (PAAm), poly(acrylic acid) (PAA), poly(methyl acrylate) (PMA), and 
poly(diethylaminoethylmethacrylate) (PDEAEMA), able to perceive the pH-variation and 
consequently to modify their structure and hydrophobicity as result of protonation or 
deprotonation of inner functional groups or of cleavage of the shell (Bawa et al., 2009). For 
example, concerning the nanogels, it has been broadly reported that pH-responsiveness is 
based on the change of their ionization state that induces a swelling/deswelling and therefore 
the release or the entrapment of various molecules. (Oishi et al., 2007). 
Another approach largely adopted is the conjugation of drugs through pH-sensitive linkers 
(Figure 15), which can be incorporated into nanocarrier structure. The conjugation protocol 
is based on the activation of functional groups of both nanocarriers and linkers (i.e. imine, 
ketal, oxime, citraconylamide, hydrazone, hydrazide, and acetal) (Lee et al., 2006). 
 
Figure 15. Representation of pH-dependent drug release from nanoparticles.  
 
Redox-responsive nanocarriers 
Redox-responsive nanocarriers are based on the difference of redox potential (~100–1000 
fold) existing between extracellular (oxidative state) and intracellular (reductive state) 
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environments. Principally, this is due to a diverse glutathione (GSH) concentration, indeed, 
the cytosolic concentration of GSH is higher (1-10 mM) than those registered in the tissues 
or in the plasma (2µM). Moreover, the cytosolic GSH level in cells with an enhanced 
oxidative stress (like tumour cells) is 7–10 fold higher than in normal cells (West and Otto 
2005). 
Therefore, NPs can be functionalized with a redox-sensitive linker, which can be conjugated 
to the drug. In this way, a high GSH concentration can cleave the spacers like those that, for 
example, presents a disulphide bridge (Adamo, Campora et al., 2014) (Figure 16).  
 
Figure 16. Glutathione (GSH) drug (D) release from PVP nanoparticles (Adamo, Campora 
et al., 2014). 
 
 
This controlled release system is especially effective for gene (DNA or siRNA) delivery, 
because it is necessary to protect the oligonucleotides outside the cell and to release them 
after their cellular internalization.  The presence of a linker with a disulphide or a thioester 
bond permits a very high (until to 40–100-fold higher) transfection efficiency if compared 
with the same complex without the spacer (Neu et al., 2007).  
Even if the disulphide bridge is the most used linkage to generate redox-sensitive 
nanocarriers, there are some disadvantages concerning their in vivo stability.  Indeed, GSH 
and cysteine are also present outside the cells and they can induce an early breakdown of the 
nanoparticles. This problem can be overcome by using multiple disulphide bonds and by 
controlling the amount of disulphide cross-links (Miyata et al., 2004). 
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Enzyme-responsive nanocarriers 
Enzymes are involved in a wide range of biochemical important functions and some of them 
can be overexpressed in some pathological conditions like in tumours. Therefore, it is 
possible to take advantage of this feature by introducing specific enzyme substrate sequences 
either directly into the nanocarrier or in the linker segment by which the drug is conjugate 
to the nanocarrier (Law et al., 2009). 
One of the most used linker is the tetrapeptide Gly–Phe–Leu–Gly, which can be cleaved by 
the cathepsin B enzyme that degrades proteins in lysosomes and is overexpressed in tumour 
cells (Duncan et al., 2009). 
Extracellular proteases, such as the matrix metalloproteases, are considered specific 
biomarkers of tumour tissues because of their capacity of proteolysis of extracellular matrix 
(ECM) and basement membranes, required for tissue remodelling and angiogenesis. 
For instance, some studies have reported the use of short peptides, with sequences cleavable 
by MMPs, as linkers between PEG chains and liposomes, polymeric nanoparticles, or iron 
oxide nanoparticles (Zhu et al., 2012). On the other hand, Haba and colleagues have 
developed a so-called “self immolative dendrimer”: after the enzymatic cleavage of the 
substrate, a complete dendrimer degradation occurs along with the simultaneous release of 
three different drug molecules (Haba et al., 2005). 
 
Thermo-sensitive nanocarriers 
Some nanocarriers are constituted by temperature-sensitive materials able to change their 
physical properties and to trigger drug release following up a local variation of the 
temperature. They are largely used to contrast some pathological conditions like tumours, 
inflammations, or infections that are characterized by a local temperature increase.  
In most cases, the nanosystems are produced to respond to variation of temperature in the 
range between 37 and 42°C, because higher or lower values could cause protein denaturation 
or loss of function (Aluri et al., 2009). In this contest, many research have been carried out 
using liposomes as thermo-responsive systems, because of the properties of their constituent 
lipids, that, following up heating, can  undergo to conformational structural changes 
associated with variations of the lipid bilayers permeability. For example, doxorubicin 
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loaded to thermo-sensitive liposomes (ThermoDox, Celsion Corporation) are in phase II trial 
for the treatment of breast and colorectal cancers, and have reached phase III trial for the 
treatment of hepatocellular carcinoma (Al-Ahmady et al., 2012). 
Moreover, some nanogels alter their swelling state in response to a temperature alteration of 
the aqueous media in which they are. Depending on the reaction, they can be classified in 
two categories: negative and positive nanogels. Negative temperature-sensitive hydrogels 
have a lower critical solution temperature (LCST) and contract upon heating above the 
LCST; while positive temperature-sensitive hydrogels have an upper critical solution 
temperature (UCST) and contract upon cooling below the UCST (Peppas et al., 2000).  
Photo-responsive nanocarriers 
The use of light as an external stimulus to induce the drug release offers many advantages, 
including ease of application and the spatial and temporal control. The photo-responsive 
properties are conferred to functional groups or linkers that, upon light irradiation with the 
proper wavelength, can alter their conformations or destabilize the nanoparticles structure 
through a molecular switch.  
The possibility to irradiate a specific area with a light source from outside of the body permits 
a space-temporal control. By contrast, one of the major obstacles of photodynamic therapy 
is the necessity to put the patient in the dark for a definite period, named “dark toxicity”, in 
order to prevent an early drug release (Jiang et al., 2005).  
Despite many advantages of this light-sensitive systems, the low penetration depth (<200 
mm) caused by the strong scattering of soft tissues has limited the use of these UV-based 
systems for in vivo applications (Wang et al., 2014). Moreover, even for in vitro applications, 
the UV light causes genetic damages to the cells. An alternative may be the near-infrared 
(NIR, 700–900 nm) irradiation, that can penetrate more deeply into soft tissues, without 
significant damage of the area of application. 
Sonic and ultrasonic-responsive nanocarriers 
Another method that permits a spatial and temporal control is based on the ultrasound 
application to trigger drug release. Usually, the most used ultrasonic-responsive nanocarriers 
are liposomes constituted mainly by PEG-lipids. Moreover, ultrasound-mediated delivery of 
genetic material from microbubbles has been used as a method for gene delivery to vascular 
37 
 
smooth muscle cells in vitro, using ultrasound that triggers the delivery of a plasmidic DNA, 
linked by electrostatic interactions. These microbubbles are acoustically ruptured near 
smooth muscle cells, under a range of acoustic pressures (0 to 950 kPa) and pulse durations 
(0 to 100 cycles) (Phillips 2010). 
 
 
Other stimuli-sensitive nanocarriers 
Even if the stimulus-responsive nanocarriers mentioned above are the most used for tumour 
therapy, there are also other nanocarriers able to respond to other stimuli and to trigger a 
controlled release. 
Electrical field-responsive nanocarriers: in most cases, they contract when exposed to an 
electric pulse and this effect persists for all the stimuli duration (Schmidt 2010). 
Magnetic field-responsive nanocarriers: they generate heat when a high-frequency magnetic 
field (HFMF) is applied to them (Lee 2010). 
Competitive ligands or ions-responsive nanocarriers: their interaction with the drug is based 
on coordinative bonds, so that the presence of a competitor with higher binding affinity can 
induce the drug release. 
Metabolic-responsive nanocarriers: They (for example nanogels) can be conjugated with an 
enzyme like glucose oxidase (GOD). In this case, in presence of glucose, the GOD–glucose 
reaction produces an acid with consequent pH reduction and collapse of the NGs that can 
release the therapeutic molecules (insulin) (Peppas and Bures, 2004). 
Nowadays it is largely adopted the possibility to have dual-responsive nanocarriers for 
design of stimuli-sensitive DDS. These systems can respond to two different stimuli, such 
as pH and ionic strength or thermo-responsiveness. Most often, these dual-responsive 
systems are produced by the combination of two monomers having responsiveness to 
different stimuli. However, the complexity of dual-responsive systems increases and 
certainly complicates the phase of the synthesis and the clinical approval of these systems. 
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Aim of the project 
Traditional chemotherapeutic agents are unable to discern the specific tumour target so, in 
order to be effective, they are administered in high doses, thus leading to a diffused toxic 
effect. The drug delivery nanosystems can solve this problem, because they can be 
functionalized to recognize a specific target and, therefore, to release the therapeutic agent 
in controlled way.  
In this contest, the research project has been focused on the analysis and the comparison of 
four different nanosystems for drug and siRNA delivery: INU-EDA-P,C-DOXO; PHEA-
EDA-P,C-DOXO; PVP-siRNA and RGO-siRNA. Two different therapeutic agents have 
been investigated in details: doxorubicin (Doxo) and siRNA for EGR-1 and Bcl-2.  
Doxorubicin has been taken into account as a drug model thanks to its features. It is a potent 
antineoplastic agent able to intercalate DNA and to induce apoptosis. Moreover, it is 
characterized by a red auto-fluorescence that permits to localize it very easily. The drug has 
been conjugated to two different polymeric systems through the same pH- sensitive 
citraconic anhydride linker (INU-EDA-P,C-DOXO and PHEA-EDA-P,C-DOXO), in 
order to compare their effects both in normal and tumour cells of the same tissue.  
Both nanoconjugates were synthesized in collaboration with Professor Giammona research 
group (University of Palermo); firstly, the cytotoxic effect inducted by the released drug was 
evaluated and, secondly, their specific localization inside the cells was analysed through 
fluorescence microscopy and flow cytometric analysis. Moreover, the specific action of 
PHEA-EDA-P,C-DOXO for tumour cells was further investigated through co-culture 
experiments with both kind of cellular lines, and their specific internalization mechanism 
was clarified by inhibiting different endocytosis pathways and by conducting lysosomal-
specific localization studies.  
On the other hand, siRNA delivery studies have been carried out comparing two very 
different systems: PVP nanogels and Graphene oxide reduced (RGO). 
PVP nanogels (NGs) have been largely characterized and studied by Dr. Adamo (from 
Ghersi research group) in collaboration with Prof. Dispenza research group.  
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Due to the intention of conjugating Egr-1 siRNA to the NPs, the Egr-1 pathway was studied 
in order to individuate the optimal condition for silencing experiments. In parallel, it was 
developed a protocol for the conjugation of Egr-1 siRNA to PVP nanogels. Once established 
the optimal condition for Egr-1 expression, silencing experiments using PVP-siRNA 
complex were carried out in order to investigate the role of NGs as siRNA delivery system. 
Furthermore, another siRNA (siRNA for Bcl-2, an important anti-apoptotic protein) was 
conjugated through a Glutathione sensitive spacer to obtain a controlled siRNA release: pre-
treating cells with the inductor of GSH (GSH-Oet), it was possible to perform silencing 
assays. 
In order to explore if a two-dimensional nanosystem would conjugate a bigger amount of 
siRNA respect to three-dimensional PVP nanogels, the use of RGO (reduced graphene 
oxide) as a possible vector for siRNA delivery was investigated.  
In collaboration with Professor Peter Griffiths research group (University of Greenwich), 
the nanosystem was investigated for its capability to link biological molecules like antibody 
and siRNA through Dynamic Light Scattering (DLS), Differential Scanning Calorimetry 
(DSC) and Raman Spectroscopy. Furthermore, Transmission Electron Microscopy (TEM) 
had underlined the planar conformation of RGO that would offer a larger surface available 
for the siRNA attachment through stacking interactions. In order to evaluate if the complex 
is a good candidate for cellular therapy, its biocompatibility and its ability to be internalized 
by cells were performed in cells treated with different amount of the complex.   
The use of nanosystems for tumour therapy can offer a large variety of advantages respect 
to the classical drug administration technics. The possibility to link higher amount of drugs 
or biological molecules, like siRNA, to a vector and to release them in a controlled way, 
strongly limits the typical side effects of the chemotherapy. In this way, all the therapeutic 
agents are released in the same time, amplifying the signal and inducing a better effect. 
Therefore, the optimization of systems with these characteristics can offer the bases for an 
innovative therapeutic approach. 
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Cell culture 
Human mammary epithelial cell line HB-2 was grown in Low-glucose Dulbecco’s Modified 
Eagle Medium (LG-DMEM, Sigma) supplemented with 10% (v/v) Fetal Bovine Serum 
(FBS) (Euroclone, Celbar), 100 units per ml penicillin G, 100 µg ml-1 streptomycin 
(Euroclone, Celbar), 2 mM l-glutamine (Euroclone, Celbar), 5 µg ml-1 hydrocortisone 
(Sigma Aldrich) and 10 µg ml-1 Bovine Insulin (Sigma Aldrich).  
Human cervical cancer cell line HeLa, human breast cancer cell line MDA-MB231, human 
Hepatic Adenocarcinoma Cell Line SK-HEP-1, Human liver hepatocellular carcinoma cell 
line HepG2 and Human normal bronchial epithelial 16HBE cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma) containing 10% (v/v) FBS (Euroclone, Celbar), 
100 units per ml penicillin G, 100 µg ml-1 streptomycin (Euroclone, Celbar) and 2 mM L-
glutamine (Euroclone, Celbar). 
ECV-304 (Endothelial Cell Vein) was grown in M199 medium (Sigma) with 10% (v/v) FBS 
(Euroclone, Celbar), 100 units per ml penicillin G, 100 µg ml-1 streptomycin (Euroclone, 
Celbar) and 2 mM L-glutamine (Euroclone, Celbar). 
Human colon cancer HCT-116 cells were grown in RPMI-1640 medium added of 10% fetal 
bovine serum (FBS), 100 U/ml penicillin, 100 μg ml-1 streptomycin and 2 mM L-glutamine. 
All the cells were cultivated at 37°C, in a humidified atmosphere of 5% CO2 and maintained 
in sterile conditions.  
Nano-conjugates 
INU-EDA-P,C-DOXO, PHEA-EDA-P,C-DOXO and RGO systems and all their variants 
were developed and characterized by Professor Gaetano Giammona research group 
(Laboratory of Biocompatible Polymers, Department of “Scienze e Tecnologie Biologiche, 
Chimiche e Farmaceutiche” (STEBICEF)) of the University of Palermo.  
 Inulin-pentyne,citraconate-doxorubicin (INU-EDA-P,C-DOXO) was a pH sensible 
system synthetized first combining pentynoic acid to an amine functionalized inulin 
derivative (INU-EDA) through  amidic link. Later, it was functionalized with 
citraconic anhydride to obtain pH-sensitive citraconate pendants, which were 
partially functionalized with doxorubicin (Figure 17). A fluorescence variant was 
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obtained by conjugation to Fluorescein Isothiocyanate (FITC) green probe (INU-
EDA-P,C-DOXO-FITC).  
 
 
Figure 17. Schematic representation of the INU-EDA-P,C-DOXO synthesis. i) Bis(4-
nitrophenyl) carbonate, 4h, 40°C, 40’; EDA; ii) EDC HCl, NHS, pentynoic acid, pH 6.8, 
r.t., 18h; iii) Citraconic anhydride, NaOH, pH 8-9, 2h; iv) EDC HCl, NHS, doxorubicin 
hydrochloride, pH 6.8, r.t., 18h.  
 
 α,β-poly(N-hydroxyethyl)-D,L-aspartamide (PHEA) was a multifunctional polymer 
that was coupled to doxorubicin though cis-citraconic acid to form PHEA-EDA-
P,C-DOXO (α,β-poly(N-hydroxyethyl)-D,L-aspartamide- pentyne,citraconate-
doxorubicin) (Figure 18).  
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Figure 18. Schematic representation of PHEA-EDA-P,C-DOXO 
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 Graphene was a single-atom thick, two-dimensional sheet of hexagonally arranged 
carbon atoms isolated from its three-dimensional parent material, graphite. The oxide 
reduced form (RGO) was a highly oxidized form of chemically modified graphene; 
their structure consisted of single-atom-thick carbon sheets with carboxylate groups 
on the periphery, where they provided pH dependent negative surface charge and 
colloidal stability. The basal surfaces contain hydroxyl (-OH) functional groups, 
which were uncharged but polar. The basal planes also included unmodified 
graphenic domains that were hydrophobic and capable of π-π interactions relevant to 
adsorption of dye molecules or some drugs (Figure 19). 
 
 
Figure 19. Representation of Graphene and RGO 
 
Graphene variants were obtained by conjugating Seprase antibody alone (RGOY) or 
with Polyvinylpyrrolidone (PVP) (RGOY-PVP) in order to reduce the stacking 
interaction between the graphene sheets. 
RGOY and RGOY-PVP were also conjugated to the red fluorescence probe Alexa 
Fluor 647 (RGOY-AF and RGOY-PVP-AF respectively) for the uptake studies.  
 
Polyvinylpyrrolidone (PVP) nanogels (NGs) were synthetized in collaboration with 
Professor Clelia Dispenza research group (Department of “Ingegneria Chimica, Gestionale, 
Informatica, Meccanica (DICGIM))” of the University of Palermo. This nanoparticles were 
synthesized by high-energy radiation (e-beam irradiation), starting from a dilute aqueous 
solution of a commercial polyvinylpyrrolidone (PVP), that can be simultaneously grafted 
with a variety of functional monomers like acrylic acid (AA). In this way, it was possible to 
obtain carboxyl functionalized PVP nanogels, named K60-0.5AA50E40, in only one-step of 
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synthesis. (Figure 20). The resulting NGs are formulated with appropriate size, shape, 
surface properties and specific chemical functionality. A variant of PVP nanogels was 
obtained by conjugating (3-[(2 aminoethyl)dithio] propionic acid) AEDP to obtain PVP-
AEDP nanoparticles. 
 
 
Figure 20. Schematic representation of the K60-0.5AA50E40 synthesis through electron 
beam (e-beam) irradiation.  polyvinylpyrrolidone (PVP) e acrylic acid (AA) were used to 
obtain PVP carboxyl functionalized nanogels K60-0.5AA50E40. 
 
 
INULIN and PHEA nanosystems 
 
Cytotoxicity studies 
Cells were seeded in 96-well plates at the density of 1 x 104 cells/well and grown in the 
appropriate medium for 24h at 37°C in a humidified atmosphere of 5% CO2. Therefore, they 
were incubated with the opportune amount of conjugates as indicated in table 1. Cells treated 
with the same concentrations of free doxorubicin were considered as positive control, 
whereas untreated cells as negative control. Cytotoxicity assay was conducted using Cell 
Counting Kit-8 (CCK-8) (Sigma Aldrich). In particular, water-soluble tetrazolium salt 
(WST-8) was added to each samples (1:10 dilution in complete medium) and incubated at 
37°C for 2h in order to permit its reduction by mitochondrial dehydrogenases of the living 
cells into soluble formazan dye that was so directly proportional to the number of living 
cells. The absorbance were determined at a wavelength of 460 nm by a microplate reader 
DU-730 Life Science spectrophotometer (Beckman Coulter). The viability was expressed as 
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percentage respect to the negative control (100% of cell viability). Each experiment was 
done in triplicate.  
Nano-system Cell culture 
Doxorubicin 
concentration (µM) 
Incubation time 
        
INU-EDA-P,C-DOXO 
HB-2 
0.5; 5; 25; 50. 24 
MDA-MB231 
     
16 HBE 
0.05; 0.1; 0.5; 5; 25; 
50. 
24; 48 HCT 116 
SK-Hep 1 
        
PHEA-EDA-P,C-DOXO  
HB-2 0.5; 2; 3.5; 5; 10; 15; 
20; 25. 
24 
MDA-MB231 
      
SK-Hep 1 
0.05; 0.1; 0.5; 5; 25; 
50. 
24; 48 
 
Table 1. Schema of different cell lines treated with a variety of doxorubicin concentrations 
conjugated to INU-EDA-P,C-DOXO or PHEA-EDA-P,C-DOXO for 24 or 48h.  
 
 
Quantitative uptake by flow cytometry 
Cells were grown in 6-well plates at 37°C and 5% CO2 until the confluence state. Afterwards, 
they were incubated with the specific conjugates at the doxorubicin concentration and times 
reported in table 2. Subsequently, the samples were washed with Phosphate Buffer Saline 
(PBS) without Ca2+ and Mg2+, detached by Trypsin-EDTA 1X in PBS (EuroClone) and 
collected by centrifugation at 1000 rpm for 5’. The pellets were re-suspended in 500µL of 
PBS and analysed by FACS-Canto cytometer (Becton Dickinson, Germany) detecting the 
green (FITC) and the red (Doxo) fluorescence emission (530–585nm respectively). For each 
sample were collected 1 x 105 events investigated by BD FACS Diva software.  
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Table 2. Schema of quantitative uptake by flow cytometry assay 
Qualitative uptake by fluorescence microscopy 
Cells were seeded into 12-well plates containing sterile coverslips at a density of 5 x 103 
cells per well with the opportune complete medium and grown for 24h at 37°C in a 
humidified atmosphere of 5% CO2. Next, each sample was incubated with the specific FITC 
variant of the nanosystems over time (see table 3) and washed with PBS in order to remove 
the nanocojugates that were not taken up by the cells. After, they were fixed with 3.7 wt % 
formaldehyde for 15 minutes. Nuclei were labelled with DAPI (dilution of 1: 10000 in water) 
for 15 minutes at room temperature. The green fluorescence relative to the nano-conjugates 
and red auto-fluorescence of the doxorubicin were detected by fluorescence microscopy 
(Leica). Untreated cells were used to calibrate the background fluorescence. 
 
Nano-system Cell culture 
Doxorubicin 
concentration (µM) 
Incubation time 
(hours) 
        
INU-EDA-P,C-DOXO-
FITC 
HB-2 
25 1; 4; 24. 
MDA-MB231 
        
PHEA-EDA-P,C-DOXO-
FITC  
HB-2 
25  1; 4; 6; 24. 
MDA-MB231 
Table 3. Schema of qualitative uptake by fluorescence microscopy assay 
 
Co-culture experiments 
The co-culture studies were conducted only for PHEA-EDA-P,C-DOXO nano-systems. 
Tumour cells MDA-MB231 (1 x 105 cells/mL) were stained with 25 µM Molecular Probe 
Nano-system Cell culture 
Doxorubicin 
concentration (µM) 
Incubation time 
(hours) 
        
INU-EDA-P,C-DOXO-
FITC 
HB-2 
25 1; 2; 4; 6; 8; 24. 
MDA-MB231 
        
PHEA-EDA-P,C-
DOXO-FITC  
HB-2 
25 0.5; 1; 2; 4; 6; 8; 24. 
MDA-MB231 
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CellTrace CFSE fluorescent stains (CellTrace CFSE Cell Proliferation Kit- Life 
technologies) by incubating for 30 minute at 37°C.  
Labelled MDA-MB 231 and unlabelled HB-2 normal cells were mixed in ratio 1:1 and were 
grown at the final density of 8 x 104 cells/well into 12-well plates containing sterile 
coverslips in complete LG-DMEM for 24h at 37°C.  
Afterwards, the samples were incubated with PHEA-EDA-P,C-Doxo or free Doxo as 
positive control (final Doxo concentration of 10 µM) for 15’, 30’, 1h, 2h, 4h, 6h, 24h. 
Following, the cells were washed twice with PBS, fixed with 3.7 wt % formaldehyde for 15 
minutes and washed again with PBS. Additionally, nuclei were stained with DAPI (1: 10000) 
for 15 minutes at room temperature. Untreated cells were considered as negative control to 
set the auto fluorescence. The samples were analysed by fluorescence microscopy (Leica). 
 
Analysis of PHEA-EDA-P,C-FITC-Doxo internalization mechanisms. 
Internalization studies was carried out both on tumour cells (MDA-MB 231) and normal 
ones (HB-2) through flow cytometry and confocal microscopy. In both experiments, the cells 
were pre-incubated for 10 minutes with PBS-G buffer (PBS with 5mM 2- deossi-D-Glucose) 
and subsequently with different endocytosis inhibitor. The endocytosis inhibitors used are 
75 µM ethyl-isopropyl amiloride (EIPA); 40 µM nystatin and 5 µM Phenylarsine oxide 
(PAO). EIPA and Nystatin were incubated 10’ at 37°C while PAO for 5’ at 37°C. Therefore, 
PHEA-EDA-P,C-FITC-Doxo (final Doxo concentration of 25 µM in PBS-G buffer) mixed 
with EIPA or Nystatin and without PAO were added and incubated for 1 h at 37°C. Samples 
incubated only with PHEA-EDA-P,C-FITC-Doxo for the same time were considered as 
positive control, while cells incubated at 4°C for 20’ and then treated with conjugates for 1h 
were used to estimate the passive internalization.  
 For flow cytometry studies, the cells were maintained in 6-well plates with the 
appropriate medium until the cell confluence. After the mentioned treatment, they 
were washed with PBS without Ca2+ and Mg2+, detached by Tripsin 1X (EuroClone) 
and centrifuged at 1000 rpm for 5 minutes. The cell pellet obtained was re-suspended 
with 0.5 mL of PBS and analysed by FACS-Canto cytometer (Becton Dickinson, 
Germany) in order to detect the green (FITC) and the red (Doxo) fluorescence 
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emission (respectively 530–585nm). For each sample were collected 1 x 104 events 
investigated by BD FACS Diva software.  
 
 For confocal microscopy studies, the cells were seeded on 12-well plates containing 
sterile coverslips at a density of 5 x 103 cells per well and grown for 24h at 37°C. 
Therefore, the cells were treated only with Nystatin inhibitor as described above and, 
after washing twice with PBS, were fixed with 3.7 wt % formaldehyde for 5 minutes. 
Nuclei were labelled with DAPI (1: 10000 in water) for 15 minutes at room 
temperature and the samples were detected by FLUOVIEW FV10i-LIV  (Olympus). 
Cells treated with PHEA-EDA-P,C-FITC-Doxo were consider as positive control 
and cells inhibited by 4°C treatment as negative control. 
Lysosomal-specific PHEA-EDA-P,C-Doxo localization studies 
MDA-MB231 cells were grown at a density of 5 x 103 cells/well into 12-well plates 
containing sterile coverslips in complete medium for 24h at 37°C. Therefore, they were 
incubated with 10µM of PHEA-EDA-P,C-Doxo for 30’, 1h, 2h, 4h, 6h and 24h. At the end 
of each time, samples were incubated with 60nM of LysoTracker® Red DND-99 (Thermo 
Fisher scientific) for 1h at 37°C, washed twice with complete phosphate buffer saline (PBS) 
and fixed with 3.7 wt % formaldehyde for 5 minutes. After different washing with PBS, 
nuclei were labelled with DAPI (1 : 10000) for 15minutes at room temperature. The samples 
were detected by confocal microscopy ( FLUOVIEW FV10i-LIV, Olympus). 
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PVP nanogels 
Small interference RNA (siRNA)  
The siRNA employed for the silencing experiments are reported in Table 4. 
siRNA  siRNA sequence (sense strand)  Modification 
Strand of 
modification 
        
Egr-1 5'-CAAUUACUAUUCCCUUUGATT-3' / / 
Egr-1 5'-CAAUUACUAUUCCCUUUGATT-3' 5'-AminoC6linker sense 
        
Bcl-2 5'-GGGAGAACAGGGUACGAUATT-3' / / 
Bcl-2 5'-GGGAGAACAGGGUACGAUATT-3' 5'-AminoC6linker sense 
 
Table 4. siRNA characteristics. 
 
Transfecting siRNA into mammalian cells using Lipofectamine 
SK-HEP-1 or HeLa cells were seeded into 6-well plates and growth at 37°C with 5% CO2. 
Hela cells were transfected with Bcl-2 siRNA; while SK-HEP-1 were treated with Egr-1 
(Early growth response-1) siRNA. The expression of Egr-1 was regulated by Hepatocyte 
growth factor (HGF) and could be influenced by the factors presented into the serum. For 
this reason, the samples were first subjected to a gradual FBS starvation (5% FBS for 48h; 
2.5% FBS for 24h; 0.2% FBS for 24h and 0% FBS for 24h) and then to HGF treatment ( 10 
mM HGF at 37°C  for 30’, 1h, 2h, 3h,and 5h).  
In all assays, 24 hours before transfection, the culture medium was substituted with medium 
without antibiotics so they were at 50% of confluence at the time of transfection.  
The appropriate amount of unmodified siRNA (Table 5) was diluted in Opti-MEM® 
Reduced Serum Medium (Thermo Fisher) without serum and mixed gently. On the other 
hand, Lipofectamine 2000 (Invitrogen) was also diluted in the same medium and incubated 
for 5 minutes at room temperature. The diluted siRNA and the diluted Lipofectamine were 
mixed and incubated for 20 minutes at room temperature in order to form the complex 
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siRNA-Lipofectamine that, after appropriate dilution in culture medium without serum and 
antibiotics, was added to the cells. In all cases, the transfection was conducted for 48 hours. 
Untreated cells were used as negative control.  
 
Table 5. Schema of Transfecting siRNA assays. 
 
Conjugation of siRNA to PVP nanogels   
First of all, PVP nanogels were sterilized using a 0.2µM filter and the samples were always 
treated in sterile conditions. They were dialysed (14 kDa) against NaOH 0.2M for 24h in 
order to deactivate Ribonuclease (RNAse) that could degrade the siRNA. After that, NGs 
were dialysed against H2O RNAse free.  
0.5mg/ml of PVP nanoparticles (108.04 pmol) were mixed with: 
 0.09 mM of EDC (1-Ethyl-(3-dimethylaminopropyl) carbodiimide) diluted in MES 
(4-Morpholineethanesulfonicacid) 2% (pH of 6.5)  
 0.18 mM of Sulfo-NHS (N-hydroxysulfosuccinimid) 
The blend was incubated for 30 min in agitation at room temperature.  
Therefore, 720 pmol of 5'-AminoC6linker siRNA were mixed and incubated for 3 hours in 
agitation at 4°C and then dialyzed against H2O RNAse free to eliminate the excess of 
unlinked siRNA.  
For the cell colure, the samples were then dialyzed against the appropriate medium.   
The amount of siRNA conjugated to NGs was determined by reading the absorbance values 
at 260 nm employing the NanoDrop 1000 Spectrophotometer. Different concentrations of 
free siRNA were used for a Standard Assay.  
siRNA  siRNA (pmol) Lipofectamine (µL) Opti-MEM (µL) 
        
Unmodified Egr-1 75 3.75 187.5 
        
Unmodified Bcl-2 100 5 250 
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Treatment with PVP-siRNA complex 
Hepatocellular carcinoma cells (SK-HEP-1) were seeded in 6-well plates and maintained at 
37°C in in a humidified atmosphere of 5% CO2. Cells were subjected to FBS starvation and 
HGF treatment as reported above and subsequently were treated for 48h with 150 pmol of 
Egr-1 siRNA conjugated with PVP NGs. Cell treated with the same amount of PVP alone 
were used as negative control.  
 
Treatment with PVP-AEDP-siRNA complex 
HeLa cells were seeded in 6-well plates and grown at 37°C with 5% CO2. Some samples 
were incubated for 2 hours at 37°C with 10mM of GSH-Oet (Glutathione reduced ethyl ester, 
Sigma Aldrich) in complete medium.  After the opportune washes with PBS, PVP-AEDP or 
PVP-AEDP-siRNA (300pmol of siRNA) complex were added for 48h. 
  
Extraction of soluble proteins 
Cells were seeded in 6-well plates maintained at 37°C in a humidified atmosphere of 5% 
CO2. After the appropriate treatment, the samples were washed with PBS without Ca
2+ and 
Mg2+, detached by Trypsin-EDTA 1X in PBS (EuroClone) and collected by centrifugation 
at 1000 rpm for 5’. The pellets were re-suspended in an appropriate volume (depending of 
the pellet size) of RIPA Buffer 1X (50mM Tris-HCl pH 7.5; 0.5% sodium deoxycholate; 
150 mM NaCl; 1% Triton X-100) supplemented of proteases inhibitors: 
 1 mM of phenylmethylsulfonyl fluoride (PMSF) against serine proteases 
 1 µM of Pepstatin A against aspartyl proteases 
 100 µM Leupeptin against cysteine, serine and threonine peptidases 
 10 mM Ethylenediaminetetraacetic acid (EDTA) against metallopeptidases 
At this point, the samples were incubated in ace for 15 minutes and constantly subject to 
micro vortex mixer treatments and then centrifuged at 10,000 rpm for 20 minutes.  
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The amount of proteins extracted presented into the supernatant were calculated by the 
Bradford assay (Bradford Reagent, Sigma), using different concentrations of bovine serum 
albumin (BSA) as Standard Assay.  
 
Western Blot assay 
20 µg of proteins were mixed with sample buffer 1X (62.5 mM Tris-HCl pH 6.8; 2.5 % SDS; 
0.002 % Bromophenol Blue; 0.7135 M (5%) β-mercaptoethanol; 10 % glycerol) and 
incubated at 100°C for 5 minutes and immediately situated in ice. The proteins were separate 
by sodium dodecyl sulfate Polyacrylamide gel electrophoresis (SDS-PAGE) at the 
opportune SDS percentage, depending of the molecular weight of the interesting protein.  
At the end, the gels and the nitrocellulose membrane (Hybond, Amersham) were washed in 
transfer buffer (20% methanol; 10% Running buffer 1X: Tris base 3 g/L-Glycine 14.4g/L) 
and the proteins were transferred from the gel to the membrane through electroblotting at 
100V e 300 mA for 90 minutes at low temperature. Blocking of non-specific binding was 
achieved by placing the membrane in a solution of non-fat dry milk (3%) overnight a 4°C. 
Therefore, the specific primary antibody (IgG produced in mouse) (see table 6) was 
incubated again overnight at 4°C; after washing with TBS-T solution (0.6% Trizma base; 
0.87% NaCl; 0.05% Tween 20), the peroxidase-linked anti-mouse secondary antibody 
(Sigma) was incubated for 2h at room temperature. After other TBS-T washes, the presence 
of the target protein was identify using "SuperSignal West Femto Maximum Sensitivity 
Substrate" (Thermo Scientific) and the chemiluminescence signal was reveal using the 
ChemiDoc XRS (Biorad). The intensity of the discovered bands was analysed by Image J 
program and β-actin was used to normalize each sample.  
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Table 6. Schema of Western blot assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Proteins % SDS PAGE 
Primary Antibodies   
(IgG) produced in 
mouse 
Peroxidase-linked 
secondary Antibodies 
Anti-mouse   
        
Egr-1 (Sigma) 12 1 µg/ml 0.04 µg/ml 
        
Bcl-2 (Sigma) 15 1:1,000 0.04 µg/ml 
        
β-actin (Sigma) 
12 
0.4 µg/ml 0.04 µg/ml 
15 
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RGO, RGOY and RGOY-siRNA systems 
Sterilization of RGO, RGOY and RGOY-PVP 
In order to obtain sterile nanoparticles for in vitro studies, sterilization protocols with 
Ethanol (EtOH) 70% (Konios D. et al., 2014) was performed:  
 RGO was suspended in EtOH 70 % (0.05 mg/ml) and sonicated (3x120 sec) in order 
to reduce the aggregation of the sheets. At this point, they were first dialysed in sterile 
H2O for 72h and they were dialysed in appropriate culture medium only for the 
biological studies.  
 RGOY and RGOY-PVP was suspended in EtOH 70% (0.05 mg/ml) and put into a 
laminar flux hood to permit the Ethanol evaporation. The samples were suspended 
in culture medium without Fetal Bovine Serum (FBS) and subjected to sonication 
cycles in a 35kHz Ultrasonic Bath (3x10 minutes) alternating by micro vortex mixer 
treatments (3x5minutes). 
 
Characterization of RGO and RGOY 
RGO and RGOY systems were characterized in collaboration with Professor Peter Griffiths 
research group (Head of Department Pharmaceutical, Chemistry and Environmental 
Science, University of Greenwich -Medway Campus) through Dynamic Light Scattering 
(DLS), Transmission Electron Microscopy (TEM), Differential Scanning Calorimetry 
(DSC) and Raman Spectroscopy.  
For the DLS analysis, the samples dispersed in water (0.05 mg/ml) were diluted 1:5 in 
bidistilled water and put into a quartz cuvette of 1mL. The size distribution were performed 
using a Malvern Zetasizer Nano-ZS (Malvern, UK). The measures were done in triplicate.  
For the Transmission Electron Microscopy (TEM), the samples were diluted in bidilled 
water at the concentration of 20 mg/ ml and were placed on copper grids with films for 
observation. After 1 min of absorption, excess liquid was blotted off with filter paper. The 
dried specimens were examined by using a JEOL JEM200CX microscope. The electron 
beam was accelerated with a voltage of 1000V. The TEM images were captured using a 
Gatan, Inc.,ORIUS SC200CCD Camera.  
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DSC measurements were conducted using a Mettler Toledo DSC 823 instrument 
(Schwerzenbach, Switzerland). Approximately, 1-3 mg samples were accurately weighed in 
standard aluminium pans. An empty pan was used as a reference. A scan rate of 10 °C/min 
was employed to heat the samples from 25 to 350 °C. Analysis was performed under a 
nitrogen purge (60 ml/min). Calorimetric parameters were analysed using STARe Software. 
Raman spectra were recorded with a LabRam Raman spectrometer (Horiba Jobin Yvon,Ltd), 
fitted with a Peltier-cooled CCD camera for detection and an Olympus BX40 microscope. 
 
Biocompatibility of RGO and RGO-PVP 
HepG2 and ECV-304 cell were seeded in 96-well plates at the density of 1 x 104 cells/well 
and maintained at 37°C in a humidified atmosphere of 5% CO2. The day after, cells were 
treated with different amount of RGO or RGOY or RGOY-PVP systems for 24h, 48h and 
72h as reported in table 7. At the end of each time, cells were incubated with 200µL/well of 
complete medium containing 0.25 mg/mL of MTT solution for 2h at 37°C. In living cell, the 
yellow tetrazole MTT is reduced to purple formazan that was solubilized with 100µL/well 
of DMSO solution and the relative absorbance was read at 490 nm wavelength on a DU-730 
Life Science spectrophotometer (Beckman Coulter). The viability was expressed as percent 
values related to the untreated cells (100% of viability). Cells treated with Polyethylenimin 
(PEI) were used as positive control. Each experiment was repeated tree times. 
 
Table 7. Schema of different cell lines treated with a variety of concentrations of RGO, 
RGOY or RGOY-PVP for 24, 48 and 72h. 
 
Nano-systems Cell culture 
Nano-systems’ concentration 
(µM) 
Incubation time 
        
RGO HepG2 12.5; 25; 50; 100. 24, 48, 72 
        
RGOY ECV-304 
0.25; 0.5; 1; 2.5; 5; 10; 15; 20; 
25; 30; 50. 
24, 48, 72 
        
RGOY-PVP  ECV-304 
0.25; 0.5; 1; 2.5; 5; 10; 15; 20; 
25; 30; 50. 
24, 48, 72 
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Uptake studies by confocal microscopy 
ECV-304 cells were seeded on 12-well plates containing sterile coverslips at a density of 
5x103 cells per well and grown for 24h at 37°C. Therefore, cells were incubated with 50 µM 
of RGOY for 15’, 30’, 1h and 2h or with 5 µM of RGOY-PVP for 15’, 30’, 1h, 2h, 4h and 
6h. At the end of each time, the samples were washed with complete phosphate buffer saline 
(PBS) and fixed with 3.7 wt % formaldehyde for 5 minutes. After other washings with PBS, 
nuclei were labelled with DAPI (1: 10000) for 15minutes and then the actin cytoskeleton 
were stained with phalloidin-FITC (1:500) per 15’. The samples were detected by confocal 
microscopy ( FLUOVIEW FV10i-LIV, Olympus). 
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Results and discussion 
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In order to compare two different nano-system models for tumour therapy, inulin (INU) and 
α,β-poly(N-hydroxyethyl)-D,L-aspartamide (PHEA) were conjugated to the anti-cancer 
drug doxorubicin (Doxo), through a pH-sensitive link (Cytraconylamide). Both the nano-
conjugates were synthetized in collaboration with Prof. Gaetano Giammona research group 
(Laboratory of Biocompatible Polymers, Department of “Scienze e Tecnologie Biologiche, 
Chimiche e Farmaceutiche” (STEBICEF)) of the University of Palermo. 
 
 
 
INU-EDA-P,C-DOXO 
 
Inulin is a natural, biocompatible and biodegradable (Van der Zee et al., 1995) 
polysaccharide constituted by linear chains of β-(1-2) fructose units carrying a glucose unit 
as reducing end-chain. To obtain the nanosystem, inulin was firstly functionalized with 
ethylenediamine (EDA) and then coupled with pentynoic acid (P) and citraconic anhydride 
(C) used for the doxorubicin (Doxo) conjugation. The forming complex was named INU-
EDA-P,C-DOXO and was characterized by Proton Nuclear Magnetic Resonance (1H NMR) 
spectroscopy, UV spectrophotometry and Size-Exclusion Chromatography (SEC) analysis 
(Table 8). These analyses permit to individuate the specific nanopolymer composition and 
some properties like molecular weight and zeta-potential. Furthermore, the shape was 
investigated through by Scanning Electron Microscopy (SEM) and the amount of drug 
release at different pH values was determined by High Performance Liquid Chromatography 
(HPLC) (data not shown) (Mauro, Campora et al., 2015).  
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Table 8. Characteristics of INU-EDA-P,C-Doxo and its precursors: molecular weight (Mw), 
polydispersity ζ-Potential and composition.         
   
 
 
      
 
Composition 
   
Sample cMw cMw/Mn 
aDDEDA       
(%) 
aDDPentine 
(%) 
aDDcitric      
(%) 
bDDDoxo     
(%) 
ζ-Pot          
(mV) 
                
INU-EDA 4 1.87 19 - - - 18.8±3.9 
                
INU-EDA-P,C 4.3 1.7 19 4.1 16.1 - 24.8±4.1 
                
INU-EDA-P,C-
Doxo 
13.3 1.62 19 4.1 16.1 8.57 18.2±7.0 
        
a Calculated by means of 1H NMR spectroscopy. 
b Calculated combining 1H NMR spectroscopy and UV spectrophotometry. 
c Obtained by SEC analysis in 0.1 M LiBr DMF solution. 
 
 
 
  
Cytotoxicity of INU-EDA-P,C-Doxo 
In order to evaluate a specific cytotoxic effect of INU-EDA-P,C-Doxo, viability assay was 
performed in different cell lines including normal cells like 16HBE and tumour cells like 
HCT 116 and SK-Hep-1. After 24h of incubation looking at the lowest nanoconjugates 
concentrations (0.05; 0.1 and 0.5 µM) no differences in the viability were observed between 
normal and tumour cells (all the samples presented a viability of 100%); but at 5 µM and, 
more and more, at 25µM and 50µM, the viability of tumor cells strongly decrease respect to 
the control. Indeed, for example, at the concentration of 5 µM, 16 HBE presented a viability 
of 84.97%, while HCT 116 and SK-Hep-1cells showed respectively values of 49.95% and 
44.44% (Figure 21, Panel A). After 48 hours (Figure 21, Panel B), the doxorubicin 
conjugated to the nano-systems started to kill also the normal cells, even though with a 
weaker effect (at 25 µM it was registered a viability of 39.40% vs. 12.12% vs. 3.07% for 16 
HBE vs. HCT 116 vs. SK-HEP-1 respectively).   
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Figure 21. Cytotoxic assay on normal (16HBE) and tumour (HCT 116 and SK-Hep-1) cell 
lines treated with INU-EDA-P,C-Doxo for 24h (Panel A) and 48h (Panel B).  
 
The specific effect of INU-EDA-P,C-Doxo was more evident comparing healthy and cancer 
cells from the same tissue. For this purpose, HB-2 and MDA-MB 231 cell lines were 
selected: they are normal and tumour cells of the breast tissue, respectively. Figure 22 shows 
the viability of both cells incubated for 24 h with different amount (0.5; 5; 25 and 50 µM) of 
INU-EDA-P,C-Doxo and free doxorubicin as positive control. In all the cases a dose-
dependent reduction of viability was observed, but with some outstanding differences. It is 
evident that the viability of HB-2 treated with the conjugates was always higher, even if 
compared to free drug-treated samples. By contrast, INU-EDA-P,C-Doxo induced higher 
mortality level on tumor cells, especially when they were incubated with the doxorubicin 
concentration of 25 µM (52% vs 32% of viability for HB-2 and MDA-MB 231 respectively). 
Comparing the effects of doxorubicin alone and doxorubicin linked to Inulin on cancer cells, 
it is evident that at low concentrations, the nanosystem was significantly less efficient; but 
at higher concentrations (25 µM) the viability of tumor cells treated with INU-EDA-P,C-
Doxo was lower than the one of tumor cells treated with plain drug  (32% against 39% 
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respectively). These data suggested that the inulin would improve the specific action of the 
doxorubicin by conferring more selectivity for tumor cells respect to the normal ones 
independently of the EPR effect.  
 
 
Figure 22. Cytotoxic assay on normal (HB-2) and tumour (MDA-MB 231) cell lines treated 
with INU-EDA-P,C-Doxo or free doxorubicin for 24h.  
 
Qualitative uptake by fluorescence microscopy 
To investigate, in greater detail, the different effect of the conjugates on normal and tumour 
cells, uptake studies were conducted using a variant of the system in which the polymer was 
stained with the green fluorescence probe FITC (INU-EDA-P,C-DOXO-FITC). In this way, 
fluorescence microscopy studies permitted to follow both Inulin and the drug released thanks 
to the FITC probe and the Doxo red auto-fluorescence. The Panel A of the figure 23 shows 
MDA-MB 231 cells incubated with the complex for different times (1h, 4h and 24h). After 
1h of treatment, the co-polymer is localized in the cytoplasm and the drug is still linked to 
it, as demonstrated by the co-localization of the two fluorescence (a-a’’’). Four hours later, 
the green mark is still in the cytosol and, in particular, in the perinuclear region, while the 
red-doxo signal appears in the nuclear compartment, suggesting that the drug has been 
already released (b-b’’’).  By contrast, in HB-2 normal cells (Panel B), after 1h of incubation, 
the green fluorescence appears muffled, punctuate and restricted in a peripheral cytosolic 
area and this organization persists even after 4h (e-e’’’). At 24h, the drug is totally confined 
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in the nuclei of MDA-MB 231 that looks damaged (c-c’’’), while it is barely presented in 
the nuclei of healthy cells that show a good morphology (f-f’’’).   
 
Figure 23. Fluorescence microscopy of MDA-MB 231 (Panel A) and HB-2 (Panel B) treated 
with INU-EDA-P,C-Doxo for 1h (a-a’’’ and d-d’’’), 4h (b-b’’’ and e-e’’’) and 24h (c-c’’’ 
and f-f’’’). Blue: nuclei; Green: Inulin; Red: doxorubicin; merge: overlay of three 
fluorescence. Magnificence 40X. 
 
 
 
A 
B 
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Quantitative uptake by flow cytometry 
The INU-EDA-P,C-DOXO-FITC uptake was further investigated in the course of time (1, 
2, 4, 6, 8 and 24h) both in normal (Figure 24, Panel A) and tumour cells (Figure 24, Panel 
B) by flow cytometry. These studies permitted to obtain also a quantitative information, 
following independently the FITC fluorescence relative to inulin (530 nm) and the 
autofluorescence of the doxorubicin (585nm). In each cytogram 1 x 105 events analysed were 
represented.  
 
 
Figure 24. Representative cytograms for detection of INU-EDA-P,C-FITC (a’-f’) and 
doxorubicin (a’’-f ’’) in HB-2 cells (Panel A) and MDA-MB 231 (Panel B) after 1h (a-a’’); 
2h (b-b’’); 4h (c-c’’); 6h (d-d’’); 8h (e-e’’’) and 24h (f-f ’’). 
 
To better explain the uptake differences in both cellular lines, the same data are reported as 
percentages in fig. 25. Until 8h of treatment both normal and tumour cells present a similar 
inulin uptake profile (8.2% vs. 8.1% for HB-2 and MDA-MB 231 respectively) suggesting 
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that the polymer has been internalized in the same manner. After 24 hours, maximum 
internalization values are registered for both samples.  
Moreover, comparing the doxorubicin uptake speed in both samples, it is notable that in 
cancer cells the red fluorescence increases proportionally over time reaching a maximum 
pick after 24h (92.7%); while, in healthy cells, the drug is internalized much more slowly, 
in a manner that resembled the copolymer until 8 hours. Indeed, from 4 to 8 hours, the 
doxorubicin and the inulin uptake percentages were about 8% and 3%, respectively. For 
longer time (24h), the drug was accumulated into the cells with a red internalization of 
92.2%.  
 
 
Figure 25. Quantitative uptake of INU-EDA-P,C-DOXO-FITC on MDA-MB 231 (Red) and 
HB-2 (Blue) cell lines: FITC: solid lines; Doxo: dashed lines.  
 
The different trends of the drug uptake in the two cell lines, suggests an initial partial drug 
release in the tumour microenvironment and followed by the free doxorubicin independent 
diffusion across cell membrane. On the other hand, in healthy cells, the whole complex 
would enter the normal cells without any substantial chemical modification as demonstrated 
by the parallel increase of both green and red fluorescences. It is more evident in Figure 26, 
that shows the same data expressed like doxorubicin/FITC fluorescence ratio inside both 
cells. In HB-2 cells, the ratio is mostly constant (about 3) over time, proving that the 
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unmodified system enters the cells and remains intact. By contrast, a proportional increase 
of doxo/FITC ratio in tumour cells is observed until 8 hours of incubation, probably because 
of a faster break of the pH sensitive Cytraconylamide bridge and the consequent drug release 
in cancer microenvironment. At 24 hours, the fluorescence of the internalized conjugate 
return to 3, the normal Doxo/FITC ratio. 
 
 
Figure 26. Relative uptake expressed as doxorubicin/FITC fluorescence ratio on MDA-
MB 231 (Red) and HB-2 (Blue) cell lines.  
 
All the data reported, suggest a specific model of action of INU-EDA-P,C-DOXO against 
tumour cells that is represented in figure 27. Tumour tissue is characterized by abnormal 
branching and wider interendothelial gaps due to damage of Tight Junctions (TJ) between 
endothelial cells and a disrupted basement membrane (Martin, 2014). Therefore, INU-EDA-
P,C-DOXO in blood vessels would across through the large gaps and extravasate to the 
malignant tissue via EPR (Enhanced Permeation and Retention) effect. Tumour 
microenvironment presents a lower pH (6.5) respect to those of normal ones (7.4) (Gerweck 
and Seetharaman, 1996) so that the acidity would be able to reverse the conjugate charge 
from negative to positive. In this way, the doxorubicin would be partially released from the 
Cytraconylamide bridge and it would  enter the cells through a simple diffusion mechanism, 
as demonstrated by flow cytometry studies. Inside the cells, the drug would be completely 
released and go into the nuclei to induce cell death, as demonstrated by cytotoxic assays. 
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Therefore, the different effects on normal and cancer cells is probably due to the difference 
of pH outside and inside the cells and to a different composition of the cell membranes. 
 
 
 
The data relative to INU-EDA-P,C-DOXO, have been reported in the paper “Self-organized 
environment-sensitive inulin–doxorubicin conjugate with a selective cytotoxic effect 
towards cancer cells” published by Royal Society of Chemistry in March 2015 (N. Mauro, 
S. Campora, C. Scialabba, G. Adamo, M. Licciardi, G. Ghersi and G. Giammona).  
 
 
 
 
Figure 27. Representation of the model act of INU-EDA-P,C-DOXO.  
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PHEA-EDA-P,C-DOXO  
PHEA (α,β-poly(N-hydroxyethyl)-D,L-aspartamide) is a multifunctional polymer  endowed 
with high water solubility and biocompatibility. Aa for Inulin, the polymer was 
functionalized with EDA and pentynoic acid (P) and then conjugated to doxorubicin thanks 
to the pH-sensitive cis-citraconic linker acid to form PHEA-EDA-P,C-DOXO complex.  
All the studies were carried out on MDA-MB 231 cancer cells and HB-2 normal cells to 
have a tumour and a normal model system of the same tissue (mammary tissue).  
Cytotoxic studies of cells treated with PHEA-EDA-P,C-DOXO 
The PHEA-EDA-P,C-DOXO cytotoxicity was assessed at 24h on the two cell models and 
compared with free doxorubicin as reported in figure 28. At low concentrations (0.5, 2 and 
3.5 µM), all the samples presents similar trends, even with a slight difference from healthy 
and cancer cells treated with the conjugates (at 3.5 µM: 73.22% vs. 64.84% viability for HB-
2 and MDA-MB 231 cells respectively). At 5 µM, HB-2 cells incubated with nanosystems 
show 75% of viability that is maintained also for higher concentrations (10, 15, 20 and 25 
µM). On the other hand, in cancer cells, PHEA-EDA-P,C-DOXO induces a cytotoxic effect 
comparable to the one registered for the free drug. In particular, at 5 µM and 10 µM the 
viability is about 55%, but at 15 µM, as well as at higher concentrations (20 and 25 µM), it 
decrease till 30% suggesting a plateaux state in which the cytotoxic activity reaches  the 
maximum level. The same trend of free and conjugated doxorubicin on MDA-MB 231 leads 
to hypothesize that the entire amount of conjugated drug would be released from the 
nanosystems at concentrations higher than 5 µM. By contrast, HB-2 cells present a different 
percentage of viability if treated with free or conjugates drug, thus suggesting that in healthy 
microenvironment or in the cells, are not optimal to permit the doxo release. Therefore, there 
is a selective activity of the polymer for tumour cells independently of the EPR effect, as it 
was supposed for inulin polymers.  
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Figure 28. Cytotoxic assay on normal (HB-2) and tumour (MDA-MB 231) cell lines treated 
with PHEA-EDA-P,C-DOXO or free doxorubicin for 24h. 
 
The cytotoxic activity of drug conjugated with the nanosystem was investigated also in 
another tumour cell line like SK-HEP-1 (human Hepatic Adenocarcinoma Cell Line) (Figure 
29). The results obtained using MDA-MB 231 were confirmed: after 24 hours of treatment 
(Figure 29, panel A), there is not a significant drug inhibition in cell proliferation using low 
doxorubicin concentration conjugated with PHEA-EDA-P,C (viability around 100% at 0.05, 
0.1 µM). Instead, at 5, 25 and 50 µM there is an evident reduction of the viability until a 
value of 40%. Stronger effect, but the same trend, is individuated also after 48 hours of 
incubation with the nanocomplex (Figure 29, panel A). Samples with free drug are used as 
control.  
 
0
20
40
60
80
100
120
0 0.05 0.1 0.5 5 25 50
C
el
l V
ia
b
ili
ty
 (
%
)
Doxorubicin (µM)
PHEA-EDA-P,C-DOXO DOXO
A 
0
20
40
60
80
100
120
0 0.5 2 3.5 5 10 15 20 25
C
e
ll
 V
ia
b
il
it
y
 (
%
)
Doxorubicin (µM)
Doxo_HB2 PHEA-EDA-P,C-DOXO_HB2
Doxo_MDA-MB231 PHEA-EDA-P,C-DOXO_MDA-MB231
69 
 
 
Figure 29. Cytotoxic assay on SK-Hep-1 tumour cell line treated with PHEA-EDA-P,C-
Doxo or Doxo free for 24h (Panel A) and 48h (Panel B).  
 
PHEA-EDA-P,C-FITC-Doxo localization studies by fluorescence 
microscopy 
To investigate if the different cytotoxic effect of PHEA-conjugated doxorubicin between 
cancer and healthy cells is really due to a different release level, localization studies were 
conducted. In order to independently follow FITC-conjugated nanosystem and the released 
red auto-fluorescence doxorubicin, a fluorescent variant of PHEA, named PHEA-EDA-P,C-
FITC-Doxo, is used. After 1 hour of incubation, the green fluorescence is lightly higher in 
tumour cells (Figure 30, Panel A, a’) than in the normal ones, where it is feeble, around the 
cells and barely present inside them (Figure 30, Panel B, e’), suggesting a slight different 
uptake rate, probably because of the diverse composition of the cellular membranes. 
Anyway, in both cases, the two fluorescence signals co-localized, demonstrating that the 
drug is still bound to the polymer, even if, in cancer samples, doxorubicin is also partially 
inside the nuclei.  
Like the inulin nanosystems, after 4h and much more after 6h, the polymer appears also 
inside the HB-2 cells, only in perinuclear region and, with a muffled and punctuates 
fluorescence (Panel B, f’), while in MDA-MB 231, the florescence is diffused (Panel A, b’). 
As at these time points, the drug release has already occurred, the red fluorescence appears 
into the nuclei of both cells. Finally, at 24h, all the systems are saturated, but the nuclei of 
MDA-MB 231 seem damaged and cell morphology is altered by the onset of apoptosis 
phenomena. 
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Figure 30.  Localization studies of PHEA-EDA-P,C-FITC-Doxo on MDA-MB 231 (Panel 
A) and HB-2 (Panel B) after 1h (a-a’’’ and e-e’’’) , 4h (b-b’’’ and f-f’’’), 6h (c-c’’’ and g-
g’’’) and 24h (d-d’’’ and h-h’’’) of incubation. Blue: nuclei, green: PHEA-EDA-P,C-FITC, 
red: Doxo. Magnificence 40 X.   
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PHEA-EDA-P,C-FITC-Doxo localization studies by flow cytometry 
The data were confirmed and examined in depth through flow cytometry following the FITC 
and the doxo fluorescence signals inside both healthy (Figure 31, Panel A) and tumour 
(Figure 31, Panel B) cells incubated with PHEA-EDA-P,C-FITC-Doxo over time (1, 2, 4, 6, 
8 and 24 hours).  
 
 
 
 
Figure 31. Representative cytograms for detection of PHEA-EDA-P,C-FITC (a’-f’) and 
doxorubicin (a’’-f ’’) in MDA-MB231 cells after 1h (a-a’’); 2h (b-b’’); 4h (c-c’’); 6h (d-d’’); 
8h (e-e’’) and 24h (f-f’’).  
 
 
72 
 
The date reported in each cytogram were collected and re-elaborated in the graph in figure 
32. An outstanding difference between normal and cancer cells is evident. The doxo signal 
in MDA-MB 231 very quickly increases over time (1, 2, 4 and 6 hours), reaching the plateau 
after 8 hours, which endures up to 24h. Even the green fluorescence increases over time, but 
very slightly at the beginning (until 8h) and then faster until 24h. On the other hand, in HB-
2 cells, the two fluorescence present similar and very low uptake values for all the time 
points analysed. Comparing with cancer samples (light green line in the graph), the FITC 
mark relative to the PHEA system (yellow line in the graph), is always lower, suggesting a 
higher uptake level in tumour cells rather than in the normal ones. Probably it depends on 
their differences of the composition and fluidity of the membranes that facilitate the 
conjugates entrance into MDA-MB231.  
 
Figure 32. Quantitative uptake of PHEA-EDA-P,C-FITC-Doxo on MDA-MB 231 (Dark 
and light Green) and HB-2 (Red and Yellow) cell lines: FITC: solid lines; Doxo: dashed 
lines.  
 
Figure 33 shows the doxo/FITC ratio over time in both cellular samples. In HB-2 the ratio 
is almost constant over time, suggesting that the unmodified PHEA-EDA-P,C-FITC-Doxo 
has probably been internalized. By contrast, in MDA-MB231, there is an increase in 8h, but 
at 24h, the ratio return to 2, the normal Doxo/FITC ratio. 
As reported for Inulin systems, the difference of FITC/doxo fluorescence ratios between 
normal and tumour cells, suggested a possible mechanism of a partial drug release in the 
tumour microenvironment. Moreover, since Doxo is bound through a pH-sensitive linker to 
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the copolymer, the lower pH would induce a partial drug release in cancer tissues, permitting 
the free drug to cross tumour cell membrane, while in the normal tissue the complex remains 
stable and enters the cells as it is.  
 
 
 
 
Figure 33. Relative uptake expressed as doxorubicin/FITC fluorescence ratio on MDA-
MB 231 (Green) and HB-2 (Red) cell lines.  
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Co-culture experiments.  
To investigate the specific selectivity of PHEA-EDA-P,C-Doxo for tumour cells respect to 
healthy ones, co-culture experiments were carried out (Figure 34). Firstly, MDA-MB 231 
cells were treated with CellTrace CFSE fluorescent dye that conferred them a green 
fluorescence (b); then, they were mixed with the same amount of unlabelled normal cells 
(a), seeded in the same plate and incubated with the conjugates. The green fluorescence 
permitted to distinguish cancer cells from the normal one even if both nuclei were labelled 
with DAPI, and the possibility to have in the same plate both cell types, would give us more 
information about the specific action of the complex. In particular, it was possible to identify 
a selective uptake after only 30 minutes of incubation (15µM PHEA-EDA-P,C-Doxo ) as 
shown in figure 33. In details, the red mark of doxorubicin is present only in the MDA-MB 
231 cells, demonstrating that there is an exclusive PHEA-EDA-P,C-Doxo localization inside 
tumour cells. This is probably due to the different composition of the two cellular types 
concerning, for example, fatty acid and proteins and determining a diverse membrane 
fluidity (Meng et al., 2004; Szachowicz –Petelska et al., 2010).  
 
 
Figure 34. Co-culture of MDA-MB 231 and HB-2 incubated for 30’ with 15 µM PHEA-
EDA-P,C-Doxo. Blue: nuclei, green: MDA-MB 231, red: Doxo. Magnificence: 40X. 
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In order to better characterize the uptake kinetic, co-culture experiments were carried out 
over time (30’, 1h, 2h, 6h and 24h), using low PHEA-EDA-P,C-Doxo concentrations and 
free drug as a control (Figure 35). After short incubation times (30’; 1h; 2h), there is an 
exclusive localization of the complexes in cancer cells, as suggested by the co-localization 
of the red and the green signals (a’’’; b’’’ and c’’’). Doxorubicin begins to appear in HB-2 
cytoplasm only after 6h of treatment (d’’’); subsequently (at 24h), the drug is into the nuclei 
of both cell lines probably because it can enter all cells through a diffusion process (e’’’) as 
it has been demonstrated for many nanosystems (Dalmark et Hoffmann, 1983).   
 
 
Figure 35. Co-culture of MDA-MB 231 and HB-2 incubated with 10 µM PHEA-EDA-
P,C-Doxo for 30’ (a-a’’’), 1h (b-b’’’), 2h (c-c’’’), 6h (d-d’’’) and 24h (e-e’’’). Blue: nuclei, 
green: MDA-MB 231, red: Doxo. Magnificence: 40X. 
 
By contrast, free doxorubicin is inside both normal and tumour cells already after 30 minutes 
of incubation, demonstrating that the copolymer PHEA is responsible for the specific 
selectivity for cancer cells (Figure 36). 
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Figure 36. Co-culture of MDA-MB 231 and HB-2 incubated with 10 µM Doxo for 30’ (a-
a’’’), 1h (b-b’’’), 2h (c-c’’’), 6h (d-d’’’) and 24h (e-e’’’). Blue: nuclei, green: MDA-MB 
231, red: Doxo. Magnificence: 20X. 
 
PHEA-EDA-P,C-FITC-Doxo internalization mechanisms. 
In most cases, classical drugs constituted by small molecules are internalized into cells 
through passive diffusion or active transport.  It is largely reported in literature that 
nanosystems, instead, enter cells via endocytosis through different mechanisms involving 
membrane components or specific cellular pathways, in dependence of kind and nature of 
the systems (Longfa Kou et al., 2013) (Figure 37). Depending of the proteins involved, 
endocytosis pathways has been classified in different groups like Phagocytosis, Clathrin-
dependent or Caveolae-dependen endocytosis and Macropinocytosis (Gary et al., 2009). To 
individuate the PHEA-EDA-P,C-FITC-Doxo internalization mechanisms, flow cytometric 
analysis and confocal microscopy assays were conducted in both cell lines, using three 
endocytic inhibitors. Ethyl-isopropyl amiloride (EIPA) is a macropinocytosis inhibitor that 
reduces cytosolic pH and, in this manner, blocks the activation of Rac1 and Cdc42 GTPases 
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that normally play a key role in the process (Kälin et al., 2010). Phenylarsine oxide (PAO) 
inhibits clathrin-dependent endocytosis through the inactivation of multiple intracellular 
targets, including major actin cytoskeleton regulators related to this specific pathway (Di 
Andrei I. Ivanov, 2008). At last, nystatin is a sterol-binding agent that links and restricts the 
function of many proteins, like kinases implicated in Caveolae-dependent endocytosis: it 
disassembles caveolae and cholesterol in the membrane.   
 
Figure 37. Intracellular nanocarrier trafficking following macropinocytosis, clathrin-
mediated endocytosis and caveolae-mediated endocytosis (Hillaireau and P. Couvreur, 
2009). 
 
First, each inhibitor was valuated for its effects on cell viability through Cell Counting Kit-
8 (CCK-8) (Sigma Aldrich) assay and none was capable of inducing any cytotoxic effect 
(data not shown). Cells treated with PHEA-EDA-P,C-FITC-Doxo but without inhibitors 
were used as negative control, while cells incubated at 4°C was used as positive control. 
Indeed, the low temperature inhibits all the active internalization pathways so that the 
conjugates would enter only by a passive process (simple diffusion). In all samples, after the 
treatment with inhibitors, the nanopolymers were incubated for 1 hour. The data concerning 
flow cytometric studies were collected and related as FITC (relative to nanosystem) or Doxo 
fluorescence percentage values in figure 38 (Pannel A and B, respectively). The results 
obtained following the two fluorescence signals were comparable. Indeed, in both cases, 
MDA-MB-231 or HB-2 cell lines treated with EIPA and PAO show similar values to the 
negative control ones, suggesting that PHEA internalization is not dependent on 
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macropinocytosis and clathrin-dependent endocytosis. By contrast, cells inhibited by 
Nystatin show lower level of fluorescence, comparable to those of the positive control (4°C),  
strongly suggesting that PHEA-EDA-P,C-FITC-Doxo enters cells by Caveolae-dependent 
endocytosis and, very slowly, by simple diffusion. It is interesting to underline that 
nystatinhas a stronger inhibition effect on tumour rather than on normal cells, confirming, 
another time, the specificity of cancer uptake.   
 
 
 
Figure 38. Effect of various endocytic inhibitors on the internalization of 25µM of PHEA-
EDA-P,C-FITC-Doxo on MDA-MB 231 and HB-2 cells after 24h (Panel A) and 48h (Panel 
B) of treatment.  
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The data above were confirmed by confocal microscopy analysis of MDA-MB231 treated 
with Nystatin, giving not only quantitative, but also morphologic information (Figure 39). 
The green fluorescence inside inhibited cells (a) is very low, according with the positive 
control (b) and it is localized on the cellular surface. By contrast, in not inhibited samples 
(c), the green dye is diffused in the cytoplasm, demonstrating that the amount of conjugates 
is higher.  
 
Figure 39. Confocal microscopy images of MDA-MB231 treated with Nystatin and 
incubated with 25 µM of PHEA-EDA-P,C-Doxo (a). Cells incubated at 4°C (b) are used as 
positive control and cell without inhibitor (c) as negative control. Blue: nuclei. Green: 
PHEA. Merge: overlay of 2 fluorescence. Magnificence 60X. 
 
 
 
 
Specific localization studies 
Depending of the nature of the molecules, endocytosis via caveolae can involve two 
divergent mechanisms (Figure 40). For examples, the virus SV40 can enter the cells though 
this mechanism, but it can escape the lysosomal degradation (Carver and Schnitzer, 2003). 
Other ligands internalized through a caveolae pathway, instead, are involved in the formation 
of early endosomes, named caveosomes, that then fuse with lysosomes following the 
classical endocytic pathway (Kiss and Botos, 2009).  
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Figure 40. The caveolae vescicular endocytic pathway 
 
To identify the pathways involved in PHEA-EDA-P,C-Doxo internalization, specific 
localization studies were conducted through confocal microscopy. In particular, MDA-
MB231 cells were incubated with the conjugates over time (30’, 1h, 2h, 4h, 6h and 24h) and 
then the lysosomal compartments were labelled with LysoTracker (Figure 41, a’- f’) in order 
to verify if a co-localization occurs. For early times of incubation (30 minutes), the 
copolymer is still largely diffused in the medium and partially situated in the cell membrane, 
suggesting that it is going inside the cells (a-a’’’). At 1h of treatment, there is a different 
localization of the green (lysosomes) and red (PHEA-EDA-P,C-Doxo) fluorescences (b-
b’’’), highlighting that the nanosystem is partially localized in the cytoplasm but not in the 
lysosomes. Their co-localization is partially observed at 2h (c-c’’’) and, after 4h (d-d’’’), 
there is a complete co-localization. These data strongly indicates that, once internalized by 
claveolae mechanism, PHEA localizes in the lysosomal compartment where the low pH 
would induce the drug release.  
Furthermore, at 6h (f-f’’’) the red mark does not more co-localize with the green one 
anymore, but it start to appear in the nuclear area, the site of doxorubicin action. At last, at 
24h cells have an apoptotic morphology, probably because of the doxorubicin effect.  
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Figure 41. Confocal microscopy images of MDA-MB231 incubated with 10 µM of PHEA-
EDA-P,C-Doxo for 30’ (a-a’’’), 1h (b-b’’’), 2h (c-c’’’), 4h (d-d’’’), 6h (e-e’’’) and 24h (f-
f’’’). Blue: nuclei. Green: Lysosomes LysoTracker-labelled. Red: Doxo. Merge: overlay. 
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All the data have permitted to hypothesize a model in which PHEA-EDA-P,C-DOXO 
complex would start to release the drug in the tumour microenvironment thanks to lower pH. 
(Maybe, it can reach the cancer site though the EPR Effect, but this aspect needs to be more 
investigated). In this way, free doxorubicin would diffuse inside the cells while the 
nanosystem would be internalized through a caveolae pathway involved lysosomes, 
following the classical endocytic pathway. It would be supposed that the low pH inside the 
lysosomes would induce the complete doxorubicin release thanks to the pH-sensitive spacer; 
once set free, the drug would go into the nuclei and induce the cellular death (Figure 42). 
 
 
 
Figure 42. Representation of the model act of PHEA-EDA-P,C-Doxo.  
 
 
 
? 
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PVP nanogels 
PVP nanogels (NGs) were synthesized in collaboration with Professor Dispenza research 
group (University of Palermo) by high-energy radiation (e-beam irradiation), starting from 
a dilute aqueous solution of a commercial polyvinylpyrrolidone (PVP K60, Aldrich) and 
using the linear accelerator at the ICHTJ of Warsaw (Poland), Electronika 10/10. In this way, 
it was possible to obtain sterile nanoparticles with appropriate size, shape, surface properties 
and specific chemical functionality. In particular, PVP was functionalized with Acrylic Acid 
(AA) in order to produce carboxyl-functionalized nanogel systems (Figure 43) that have 
been characterized by DLS, FTIR and NMR (Dispenza et al.,2012; Dispenza et al., 2013). 
NGs have been largely characterized and studied by Dr. Adamo (from Professor Ghersi 
research group). In particular, their fully biocompatibility was demonstrated through in vitro 
studies like cells viability assay, valuation of apoptotic activation and Acridine Orange (AO) 
stain for DNA damage analysis (Dispenza et al., 2013; Adamo, 2013). Furthermore, the 
nanoparticles were able to conjugate biological molecules, like doxorubicin, for tumour 
therapy and/or specific ligands (like monoclonal antibodies) to recognize receptors into the 
target cells, for targeting activities (Adamo, Campora et al., 2014; Adamo, 2013). Moreover, 
recent studies had demonstrated also the possibility to link a small oligonucleotide that 
remained functional after the conjugation process (Dispenza et al., 2013). 
 
 
Figure 43. Schematic representation of P*(0.50)AA50 nanogels. 
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Egr-1 pathway and Egr-1 silencing by siRNA 
Egr-1 pathway studies 
Patients with hepatocellular carcinoma (HCC) have high serum levels of the hepatocyte 
growth factor (HGF) that is associated with the progress of the desease. In particular, HGF 
can induce the activation of the zinc finger transcription factor Egr-1 (Early growth response-
1) that is involved in the transcription of metalloproteases, like MMP-2 and MMP-9, able to 
degrade the extracellular matrix (ECM) and to induce tumour metastasis (Ozen et al., 2012) 
(Figure 44). It is reported that Egr-1 is also implicated in angiogenesis by regulating the 
transcription of vegf gene (Hee Lee et Ryong Kim, 2009). Therefore, Egr-1 would be a good 
candidate for gene silencing in tumor therapy.  
 
 Figure 44. The HGF pathway on HCC cell lines. 
 
In order to determinate the best conditions to induce Egr-1 expression, the effect of HGF 
was studied. Fetal bovine serum (FBS) contains many growth factors able to interfere with 
the expression of genes like Egr-1; therefore, SK-HEP-1 cells were subjected to a gradual 
serum starvation (see material and methods) before the HGF incubation (10 ng/ml).  
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After 1, 2 and 3hours of treatment, Egr-1 expression was investigate by Western Blot 
analysis (Figure 45). Data elaborated by ImageJ program, reveals a higher protein expression 
after 3h of treatment. For longer time, the amount of Egr-1 expressed remains stable (data 
not shown).   
 
 
Figure 45. Egr-1 expression after HGF treatment. A:Western Blot analysis of Egr-1 
expressed in SK-HEP-1 after 1h, 2h and 3h of HGF treatment. B: Graph of the Egr-1 
expression in HGF treatment time-dependent way (ImageJ).  
 
 
Egr-1 silencing by siRNA using Lipofectamine 
Once established the optimal conditions to induce the maximum expression of Egr-1, 
silencing experiments were conducted. In order to study siRNA efficiency, lipofectamine 
system was used. As shown in figure 46, Egr-1 siRNA is able to reduce the expression of 
the protein both with and without HGF treatment, if compared to untreated cells. 
Remarkably, after 3 hours of treatment with HGF, the silencing is stronger , suggesting that 
this is the best condition to perform the other experiments.  
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Figure 46. Egr-1 expression after HGF treatment (3h) and/or Egr-1 siRNA treatment (48h). 
A:Western Blot analysis of Egr-1 expressed in SK-HEP-1. B: Graph of the Egr-1 expression.  
 
 
Conjugation of modified siRNA to PVP nanoparticles 
In order to increase the efficiency of the siRNA against tumour cells, Egr-1 siRNA was 
conjugated to PVP nanogels functionalized with carboxyl groups. The possibility to 
functionalize these kind of nanoparticles makes them optimal candidate for siRNA delivery. 
Indeed, in this contest, a modified siRNA, with an AminoC6linker at 5’ end of the sense 
strand, can be used. The covalent bond stabilizes the siRNA and the nature of the nanogels 
protects it from the degradation. 
A conjugation protocol was developed using EDC and Sulfo-NHS reagents. EDC reacted 
with carboxylic acid groups of the NGs to form an intermediate that was easily displaced by 
nucleophilic attack from the primary amino group of the siRNA. The primary amine formed 
an amide bond with the original carboxyl group, and an EDC by-product was released as a 
soluble urea derivative. Sulfo-NHS was also added to improve efficiency or create dry-stable 
(amine-reactive) intermediates. EDC coupled NHS to carboxyl group of PVP, forming an 
NHS ester that is considerably more stable than the intermediate, and is important to have 
an efficient conjugation to the amino group of the siRNA at physiologic pH (Figure 47).  
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Figure 47. Representation of siRNA- PVP conjugation protocol. Number 1: PVP nanogel; 
Number 2: 5'-AminoC6linker modified siRNA.   
  
The amount of siRNA conjugated to the nanoparticles was determined by a spectrophometric 
analysis using the NanoDrop 1000 Spectrophotometer. A standard curve were constructed 
reading at 260nm the absorbance of serial dilutions of free siRNA (Figure 48). The 
absorbance relative to PVP nanogels were used as blank to read the conjugated samples. By 
interpolating their optical density (OD) to the standard trend, it was possible to identify that 
6.25 ng/µl of 5'-AminoC6linker modified Egr-1 siRNA were conjugated to PVP.  
 
 
Figure 48. Quantification of siRNA conjugated to PVP nanogels. A: standard curve of serial 
dilutions of free siRNA. 
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Egr-1 silencing by siRNA through PVP-siRNA complex 
 
PVP ability to deliver siRNA into cells and the efficiency of the oligonucleotides against 
their target were tested by treating SK-HEP-1 cells with the complex. Cells were incubated 
for 48 h with 150 pmol of Egr-1 siRNA-conjugated nanoparticles. Western blot analysis 
shows that Egr-1 is less expressed in treated cells. Indeed, the densitometric analysis 
(ImageJ) shows a silencing of 45.9% respect to cell incubated with nanogels alone (Figure 
49). 
 
 
Figure 49. Silencing by siRNA-PVP nanogels. A: Western Blot analysis of Egr-1 expressed 
in SK-HEP-1 after PVP-siRNA treatment. B: Graph of the Egr-1 expression. 
 
 
These results demonstrate that PVP nanogels are optimal candidates for siRNA delivery. 
Therefore, siRNA remains stable when linked to the nanogels, so that the entire complex is 
able to enter the cells.  Then the oligonucleotide is released (probably thanks to a competition 
mechanism with the Dicer complex), and it can exert its role reducing the expression of its 
target. In this way, a higher amount of oligonucleotides can reach the target site, thus 
avoiding the problem of high degradation often observed in tumor therapy.   
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Bcl-2 silencing by siRNA 
Conjugation of modified siRNA to PVP nanoparticles through AEDP 
Once established the PVP capacity to target a siRNA for gene delivery, the system was 
improved on the ability to release the oligonucleotide in a controlled way. Recent studies 
conducted by Dr Giorgia Adamo of the University of Palermo (Department of “Scienze e 
Tecnologie Biologiche Chimiche e Farmaceutiche”- STEBICEF) have been demonstrated 
that doxorubicin, linked to PVP nanogels through AEDP spacer, was released in a stimuli-
responsive manner into tumour cells. AEDP (3-[(2 aminoethyl)dithio] propionic acid) is a 
small molecule with a disulphide bridge in the middle, and an amino terminal and a carboxyl 
terminal. In this manner, it links the carboxyl group of the functionalized nanoparticles at 
one extremity and, the amino group of the modified siRNA at the other extremity. The 
presence of the disulphide bridge makes it sensible to the redox state of the 
microenvironment. When the NG is in the extracellular environment, the cargo remains 
linked to PVP-AEDP; but when it enters tumour cells, characterized by a high Glutathione 
(GSH) level the disulphide bride is broken and  the drug is released (Adamo, 2013).  
PVP-AEDP nanogels, synthetized by Professor Dispenza research group (University of 
Palermo), were conjugated to Bcl-2 5’-AminoC6linker (see materials and methods) (Figure 
50). 
 
Figure 50. Conjugation of PVP nanogels first to AEDP spacer (PVP-AEDP) and then to 
Bcl-2 siRNA (PVP-AEDP-siRNA). 
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The amount of siRNA conjugated was calculated by spectrophotometric analysis using 
NanoDrop 1000 Specrophotometer, as evaluated before for PVP-Egr-1 siRNA complex. The 
absorbance values of serial dilutions of siRNA permitted to obtain the standard curve with a 
coefficient of determination (R2) of 0.9992 (Figure 51, Table and Panel A). Comparing the 
spectra of PVP-AEDP and PVP-AEDP-siRNA nanosystems (Figure 51 Table and Panel B),  
an increase of the absorbance values at 260 nm (typical wavelength to quantify nucleic acids) 
is evident, suggesting that the siRNA is conjugated to PVP-AEDP. It was obtained a 
conjugation of 5.6 ng/µL of siRNA.  
 
Figure 51. Quantification of siRNA conjugated to PVP nanogels. A: standard curve of serial 
dilutions of free siRNA. B PVP-AEDP and PVP-AEDP-Bcl-2 siRNA spectra. 
 
Bcl-2 silencing by siRNA through PVP-AEDP-siRNA complex 
To test a specific release mechanism mediated by Glutathione (GSH), HeLa cells were 
seeded in 6-well plates. They were treated with GSH-Oet (Glutathione reduced ethyl ester) 
that increases the Glutathione concentration inside the cells until 10 mM (GHS typical 
concentration of tumour cell cytoplasms) (Anderson et al., 1985; Koo et al., 2011). 
Therefore, the cells were incubated with PVP-AEDP-siRNA nanogels (300 pmol of siRNA 
for Bcl-2 targeting). Cells treated with PVP-AEDP NGs, were used as control. In order to 
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clarify the effect of Glutathione, samples were compared with untreated cells and incubated 
with PVP-AEDP alone or conjugated with the oligonucleotide. Western blot analysis (Figure 
52) shows that without GSH-Oet treatment, there is no a significant silencing of the target 
protein, indeed the intensities of Bcl-2 bands are very similar. By contrast, in samples 
subjected to the action of the inductor of GSH, substantial difference is evident. Indeed, in 
the specimen incubated with PVP-AEDP-siRNA NGs, the band relative to Bcl-2 protein is 
almost totally disappeared respect to the negative control (cells incubated with PVP-AEDP 
NGs).   
 
Figure 52. Western blot analysis of Bcl-2 expression in HeLa cells. 
 
 
These preliminar results suggested that PVP nanoparticles would be used as vehicles for 
siRNA delivery. In particular, adding the  AEDP linker would permit a controlled release of 
the siRNA glutathione-mediated and therefore a specific action against tumour cells for 
cancer therapy. Anyway the validation of the data with specific analysis of the RNA 
expression by RT-Real Time PCR  needs to be done.  
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GRAPHENE 
Reduced graphene oxide (RGO) consists of carboxyl-graphene carrying some hydroxyl 
group in the core and carboxyl functions in the “perimeter” that would permit the 
conjugation to biological molecules, like antibodies. The bi-dimensional and planar nature 
offers a large surface area for steaking interactions, for examples with nucleic acids, like 
siRNA. The systems were synthetized in collaboration with Dr. Nicolò Mauro (from 
Professor Giammona research group, Laboratory of Biocompatible Polymers, Department 
of “Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche” (STEBICEF)- University 
of Palermo) and their characterization was conducted in collaboration with Professor Peter 
Griffiths research group (Head of Department Pharmaceutical, Chemistry and 
Environmental Science, University of Greenwich -Medway Campus). 
 
Sterilization and characterization of RGO systems.  
 
RGO had a size more high then 0.2µm, so that it was impossible to sterilize with 0.2 µm 
filter. Therefore, a sterilization protocol was performed by treating the samples with 70% 
ethanol (EtOH) in sterile conditions, as described in materials and methods. 
To evaluate any possible effects on RGO due to the EtOH treatment, Raman spectroscopy 
and Differential Scanning Calorimetry (DSC) analyses were carried out. Raman 
spectroscopy supplies information about the inner atomic structure of the sample through a 
spectrum analysis. As shown in figure 53, comparing untreated and EtOH treated samples, 
there are no differences in their spectra . In both cases, two peaks are present: D and G bands 
correspond to sp2 and sp3 carbon stretching modes, suggesting that Ethanol does not change 
the molecular properties.  
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Figure 53. Raman Spectroscopy of RGO untreated (RGO_1) or treated with EtOH 70% 
(RGO EtOH 70%). 
 
On the other hand, DSC give data relative to the chemical characteristics of the samples, like 
melting point and enthalpy. Even this analysis did not point out any considerable alterations 
induced by the treatment. Untreated RGO has a melting temperature of 215 °C, while RGO-
EtOH 70% of 216.2 °C, this little difference  is considered not significant. The diverse peak 
areas depend only by the different amount of samples used (Figure 54).  
 
 
 
SAMPLES PEAK AREA (J/g) Ti (°C) Tpeak (°C) Tf (°C) 
RGO -649 178.9 215 249.3 
RGO-EtOH -483 199.3 216.2 236.3 
 
Figure 54. DSC Thermograms of RGO untreated (RGO_1) or treated with EtOH 70% (RGO 
EtOH 70%). 
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Furthermore, the nanosystem shape was  investigated through Transmission Electron 
Microscopy (TEM) (Figure 55). The image clarifies the bidimensional nature of the RGO 
that appears like lamellar sheets, as expected. 
 
Figure 55. TEM analysis of RGO after EtOH treatment.  
 
 
 
Biocompatibility of sterile RGO systems 
Biocompatibility of RGO was tested on HepG2 cell lines. The samples were incubated with 
6.25, 12.5, 25 and 50 µg/mL of RGO in DMEM medium for 24h, 48h and 72h (Figure 56). 
Untreated or treated with Polyethylenimine (PEI) (that, in solution, presents a cellular toxic 
effect) cells were used as negative and positive control respectively. In all cases, the viability 
is always higher than 80%, even after 72h of incubation with the highest concentration of 
RGO (50µg/mL), suggesting that the complexes are biocompatible.   
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Figure 56. Biocompatibility of RGO systems on HepG2 cells after 24 hours (a), 48 hours 
(b) and 72 hours (c) of treatment. 
 
 
RGO conjugated to an antibody: RGOY 
In order to optimize its function as vector for drug delivery, the complex was analysed for 
its capacity to bind biological molecules. For this purpose, an antibody conjugation was 
performed in collaboration with Dr.  Nicolò Mauro (from Prof. Giammona research group): 
the Seprase antibody was conjugated to the carboxyl groups of RGO to form the RGOY 
systems (Figure 57). 
Samples were suspended in culture medium without Fetal Bovine Serum (FBS), because it 
contains many factors that facilitate the aggregation of the graphene sheets and, before all 
the experiments, RGOY was sonicated in 35 kHz Ultrasonic Bath many times (10’x 3times) 
in order to reduce the stacking interactions.  
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Figure 57. Conjugation of RGO to an antibody to obtain RGOY  
 
To confirm the binding of the antibody to RGO, DSC analysis and Raman Spectroscopy 
were carried out. Raman Spectroscopy shows the same trend for both samples (Figure 58), 
but, through DSC analysis, a difference in the melting point peaks is evident: 204 °C and 
215°C for RGO and RGOY, respectively. This shift is probably due to the presence of the 
conjugated antibody (Figure 59).  
 
 
Figure 58. Raman Spectroscopy for RGO and RGOY samples. 
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Figure 59. DSC Thermograms of RGO and RGOY 
 
In order to obtain information about the size and population distribution of the complex, the 
Dynamic light scattering (DLS) was performed. Surprisingly, the data reveal a difference in 
the dispersion grade of the samples in solution: the peak area of RGO is wider than the 
RGOY one (368.9 vs. 263.6, respectively) (Figure 60). This suggests the presence of 
complexes of different size in RGO solution,probably due to non-specific interactions.In 
RGOY solution the population is more homogeneous, probably because of the presence of 
the antibody linked to each complex that limits the stacking interactions.  
 
 
 
Figure 60. DSL analysis of RGO and RGOY systems 
SAMPLES PEAK AREA (J/g) Ti (°C) Tpeak (°C) Tf (°C) 
RGO -649 178.9 215 249.3 
RGOY -35.3 160.8 204.5 220.8 
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The shape of the system conjugated with antibody was also investigated by TEM (Figure 
61). Again, the image reflects the bidimensional nature of the samples.  
 
 
Figure 61. TEM analysis of RGO and RGOY 
 
 
Cellular biocompatibility and uptake studies of RGOY-AF 
In order to investigate the biocompatibility and the cellular uptake, the system was 
conjugated to the red fluorescence probe Alexa Fluor 647 (RGOY -AF) (Figure 62). 
 
 
 
Figure 62. Conjugation of RGOY to Alexa Fluor 647 probe to obtain RGOY-AF  
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Biocompatibility assay of RGOY-AF was performed on ECV-304 cell line. Cells were 
incubated for 24h, 48h and 72h with different concentrations of particles: 0.25, 0.5, 1, 2.5, 
5, 10, 15, 25, 30 and 50 µg/ml. As shown in figure 63, the viability is 100% (as the untreated 
cells are considered with 100% of viability). Cells treated with doxorubicin and used as 
negative control have a higher mortality, in dependence on  the treatment duration and the  
RGOY-AF concentration. Even after 72 hours of incubation with 50 µg/ml of RGOY, cells 
are 85.5% viable, suggesting that the particles are biocompatible.  
 
 
Figure 63. Biocompatibility of RGOY systems on ECV-304 cells after 24 hours (a), 48 
hours (b) and 72 hours (c) of treatment. 
 
 
 
Once the absence of cytotoxicity of RGOY-AF was established, uptake studies were carried 
out in order to analyse the specific particles localization inside the cells and their possible 
effects on the cytoskeleton component over time. For this purpose, ECV-304 cells were 
stained with phalloidin-FITC, marking the actin cytoskeleton, and with DAPI, to stain the 
nuclei (Figure 64). After 15 minutes of incubation, the red fluorescence of RGOY-AF is still 
diffused in the media and is partially present on the cells surface (a’’’). After 1 h (c’’’), the 
RGOY-AF red signal is higher and it starts to appear also in the cytoplasmic compartment. 
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The red signal increase with the duration of the treatment 2h (d’’’), suggesting that the 
particles are internalized in a time- dependent way.  
 
 
 
 
 
 
Figure 64. Localization studies of RGOY-AF on ECV-304 after 15’ (a-a’’’), 30’ (b-b’’’), 
1h (c-c’’’) and 2h (d-d’’’) of incubation. Blue: nuclei, green: Phalloidin red: RGOY-AF. 
Magnificence 60 X.   
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RGOY-siRNA systems 
 The RGO is synthetized in a very simple manner, starting from graphite, easily obtainable 
at low cost, and this permits to synthetize a large amount of nanosystems. Furthermore, 
because of its bidimensional nature, it can offer a very big surface available for stacking 
interactions with many molecules. For example, the conjugation with planar bases of small 
oligonuotides like a siRNA is very simple to realize and would permit to link a higher amount 
of them. Starting from this idea, Dr. N. Mauro (from Prof. Giammona research group) 
conjugated RGOY systems to Egr-1 siRNA (RGOY-siRNA) (Figure 65).  
 
 
Figure 65. Conjugation of RGOY to Egr-1 siRNA to obtain RGOY-siRNA  
The conjugation was confirmed by Electrophoresis assay and Atomic Force Microscopy 
(AFM) (data not shown, Dr. N. Mauro), and by DSC analysis (Figure 66).  As it can be seen 
from the graph,  RGO and RGOY-siRNA samples are characterized by different melting 
points: 215 °C and 196.2 °C respectively. 
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Figure 66. DSC Thermograms of RGO and RGOY-siRNA 
Furthermore, the complex was also characterized through DLS analysis and Raman 
spectroscopy (Figure 67). RGOY-siRNA and graphene have the same peculiar two peaks: 
D and G bands correspond to sp2 and sp3 carbon stretching modes (a). Conversely, RGOY-
siRNA has a size of 149.7 nm with a good Polydispersity Index (PdI) of 0.516. Stunningly, 
compared with the RGOY size (263.6 nm), it is evident that the presence of siRNA reduces 
the size of the complexes (149.7 nm), probably because of its negative charge. Indeed, it is 
presumable that the repulse force between the negative siRNAs limits the staking 
interactions of the RGOY sheets, resulting in a lower size of the aggregates.  
 
Figure 67. Raman spectroscopy (a) and DLS analysis (b) for RGOY-siRNA systems 
SAMPLES PEAK AREA (J/g) Ti (°C) Tpeak (°C) Tf (°C) 
RGO -649 178.9 215 249.3 
RGOY-siRNA -154 164.8 196.2 224.1 
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The possibility to link an oligonucleotide as a siRNA, makes the reduced graphene oxide an 
optimum candidate for gene delivery in tumour therapy. Furthermore, its ability to link an 
antibody can be used for specific targeting. 
 
RGOY-PVP systems 
A high reduction of the staking interactions between the graphene sheets was obtained by 
conjugating RGOY particles to Polyvinylpyrrolidone (PVP) (RGOY-PVP).  These systems 
were synthetized in collaboration with Professor Gaetano Giammona research group that 
conjugated them to the red fluorescence probe Alexa Fluor 647, to generate the complex 
RGOY-PVP-AF.  
Biocompatibility was tested for the ECV-304 cells using different RGOY-PVP 
concentrations (0.25, 0.5, 1, 2.5, 5, 10, 15, 25, 30 and 50 µg/ml) (Figure 68). Also using this 
complex, the viability of cells is about 100% after 24h, 48h and 72h of treatment. 
 
 
Figure 68. Biocompatibility of RGOY-PVP-AF systems on ECV-304 cells after 24 hours 
(a), 48 hours (b) and 72 hours (c) of treatment. 
 
The internalization studies were conducted through confocal microscopy and revealed a 
time-dependent uptake (Figure 69). In particular, after 15 minutes (a’’’), the RGOY-PVP-
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AF is still dispersed around the cells and partially localized in correspondence to the plasma 
membrane. It starts to go inside the cells and situates in the cytoplasm after only 30 minutes 
or more (1 hour of treatment), when the red fluorescence inside the cells is higher. The signal 
increases  after 2 hours of treatment, when  the particles appear localized in the perinuclear 
area (d’’-d’’’). For longer incubation times, the red mark is even brighter , and it is   
especially localized around the nucleus compartment.  
 
 
Figure 69. Localization studies of RGO-PVP on ECV-304 after 15’ (a-a’’’), 30’ (b-b’’’), 1h 
(c-c’’’), 2h (d-d’’’), 4h (e-e’’’) and 6h (f-f’’’) of incubation. Blue: nuclei, green: Phalloidin 
red: RGO-PVP. Magnificence 100 X.   
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Conclusion 
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Cancer is one of the most terrible diseases for the majority of world population and the 
principal cause of death worldwide (Globocan, 2014). The only approach used consists on 
the traditional anti-tumour drug administration technics, though they present many 
limitations because of their nonspecific action and consequently of the diffused side effects.  
Therefore, in the last decades, Drug delivery system has been object of interest of many 
researchers. Indeed, it offers the basis for a modern form of tumour therapy thanks to the 
possibility of using nanocarriers able to recognise the target site and to release the therapeutic 
agent in a controlled manner.  
In this contest, the PhD project has been developed in order to compare four different 
nanosystems for tumour therapy: INU-EDA-P,C-DOXO; PHEA-EDA-P,C-DOXO; PVP-
siRNA and RGO-siRNA.  
The polymeric nanocarriers Inulin and PHEA were conjugated to the antineoplastic drug 
doxorubicin (Doxo) through the same pH sensitive spacer, in order to compare them and 
individuate the more efficient. Both systems were analysed for their capacity to induce 
cellular death (using viability assays) and to be internalized (by fluorescence microscopy 
and flow cytometric analysis) comparing healthy and tumour cells from the same tissue (HB-
2 and MDA-MB 231 cell lines, respectively). It is evident that the viability of HB-2 treated 
with different concentrations of either conjugates is always higher, not only respect to 
tumour cells, but also if compared with samples treated with the free drug, suggesting that 
the nanoconjugates confer more selectivity for tumour cells respect to the normal ones, 
independently of the EPR effect. This specific action is more evident for cancer samples 
treated with PHEA-EDA-P,C-DOXO as it is evident comparing the two viability graphs 
(Figure 22 and 28). Indeed, the trends relative to the two cell lines start to diverge at lower 
concentration of PHEA-EDA-P,C-DOXO (5 µM) compared with those of INU-EDA-P,C-
DOXO (25 µM).  In particular, MDA-MB 231 cells show the same trend if treated with 
PHEA or free drug (from 3.5µM to 25µM), suggesting that all the drug conjugated to the 
nanosystem has been released (Figure 28).  
Uptake studies through fluorescence microscopy were conducted using green fluorescence 
variant of both systems (INU-EDA-P,C-DOXO and PHEA-EDA-P,C-DOXO) so that it was 
possible to follow them and, simultaneously, to follow the doxorubicin red auto-
fluorescence. The images (Figure 23 and 30) show a good internalization of both 
nanosystems in tumour cells: after 1h of incubation the drug is still bound to the polymers 
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(indeed, the green and red fluorescence signals from the nanopolymers itself and from the 
doxorubicin co-localized in the cytoplasm), while after 4h the doxorubicin starts to go inside 
the nuclear compartment whereas the nanocarriers remainn in the cytoplasm. A different 
situation were registered for normal cells: in both cases, the green fluorescence appears 
muffled, punctuate and restricted in peripheral cytosolic area even after 4 hours, thus 
demonstrating a different uptake grade between normal and tumour cells, probably because 
of their dissimilar membrane composition.  
This difference is more evident looking the quantitative uptake analysis data from flow 
cytometry.  While in HB-2 cells the doxorubicin and polymers (Inulin or PHEA) uptake 
profiles follow the same tendency, in MDA-MB 231 they are very different (Figure 25 and 
32): the red fluorescence (Doxo) inside the cancer cells increases faster than green marck 
(polymer). Therefore, these data reveal that, probably, there is a partial drug release in the 
tumour microenvironment. It is widely known that cancer tissue presents a lower pH (6.5) 
compared to the one of healthy microenvironment (pH 7.4) (Gerweck and Seetharaman, 
1996). Therefore, as the drug is bound through a pH-sensitive linker to the copolymers, the 
lower pH would induce a partial doxorubicin release in cancer tissues, so that it would diffuse 
into tumour cells; while, the physiological pH of the normal tissue, cannot permit the 
controlled release so that the entire complexes would go inside the cells. In details, 
comparing the results of using Inulin and PHEA nanosystems, it is evident that the uptake 
difference between normal and tumour cells is more prominent in the second one. It is 
probably due to the different polymeric composition and therefore to the different capacity 
to be internalized.  
In light of these data that support PHEA-EDA-P,C-DOXO as the most efficient nanocarrier, 
its preferential uptake into tumour cells was further investigated through co-culture 
experiments: the same number of MDA-MB 231 and HB-2 cells were grown together and 
incubated with the selected nanosystem (Figure 34-35). Fluorescence microscopy confirms 
a faster internalization into the cancer line. Furthermore, also the endocytic pathway and the 
subsequent itinerary inside cells were investigated using specific endocytosis inhibitors (by 
flow cytometric analysis and confocal microscopy, Figure 38 and 39) and a specific 
lysosomal probe (byconfocal microscopy, Figure 41) respectively.  
Therefore, all the data have permitted to hypothesize a model in which PHEA-EDA-P,C-
DOXO complex would start to release the drug in the tumour microenvironment thanks to 
the low pH. In this way, free doxorubicin would diffuse inside the cells, while the 
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nanosystem would be internalized through a pathway involving in the formation of caveolae, 
that progressively would fuse with lysosomes, following the classical endocytic pathway. It 
would be reasonable to think that the low pH inside the lysosomes would induce the 
complete doxorubicin release thanks to the pH-sensitive spacer; once set free, the drug would 
go into the nuclei and induce the cellular death (Figure 42). 
Even if the data obtained explain very well the PHEA-EDA-P,C-DOXO action mechanism, 
this model needs to be more investigated. It is very important to know how the nanocomplex 
reaches the tumour target site (we would suppose through the EPR Effect). Furthermore, 
even if it is evident a preferential ability of the complex for tumour cells, it will be possible 
to add a targeting molecule, able to recognise the specific tumour site to increase its selective 
character. Collectively, all the data support a PHEA-EDA-P,C-DOXO action model  in vitro, 
but needs to be confirmed through in vivo experiments. 
siRNA delivery studies have been conducted by comparing two different nanosystems 
conjugated with anti-tumour siRNA: Egr-1 involved in the progress of hepatocarcinoma and 
Bcl-2 related to the apoptotic pathway in cancer cells. 
The choise of these particular nanosystems depends on their nature and their ability to link 
siRNA. PVP nanoparticles are nanogels with a three-dimensional structure functionalized 
with carboxyl groups that allow a covalent binding to the amine group of modified siRNA. 
Its tri-dimensional structure would facilitate the oligonucleotide protection and limit its 
degradation. Instead, RGO is a two-dimensional system in which the planar conformation 
would favour the stacking interation with a larger amount of unmodified siRNA and the 
siRNA release would be promoted by a competition mechanism.  
PVP studies had demonstrated their good propensity as siRNA delivery system. Indeed, they 
are able to link modified siRNA (Figure 48), without any alteration of their functionality, as 
indicated by western blot analysis (Figure 49). Tumour cells have high cytoplasmic level of 
GHS compared to normal ones, and this feature can be used to achieve a controlled release 
mechanism.  For this purpose, the introduction of AEDP, with a disulphide bridge in the 
middle, permits a controlled release GHS-mediate and a higher release grade into the cells 
(Figure 52).  
Western blot analysis suggests a reduction of target protein expressed due to the siRNA 
action, thus demonstrating the system efficiency, anyway the RNA expression analysis by 
RT-real time PCR still needs to be done. 
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Preliminary studies were conducted also with graphene nanosystems. It is such an innovative 
system as DDS, that only few papers have been already published. Its nature, as well as the 
possibility to synthesize it at low cost, have made Graphene nanosystems very interesting in 
tumour therapy in the last years. As it is not very well characterized, the initial approach was 
very complicated by its aptitude to form aggregates that have limited its sterilization.  
Very interesting results were obtained through a collaboration between University of 
Palermo (Professor Giammona and Professor Ghersi research groups) and Greenwich 
University (Professor Griffiths research group). Together we developed a sterilization 
protocol using Ethanol: it does not alter graphene specific features, as demonstrated through 
DLS and DSC analyses, TEM and Raman spectroscopy. Graphene aptitude as vector for 
drug delivery is evident thanks to its capability to link antibodies (as possible specific 
targeting molecules) or siRNA (for tumour therapy). Furthermore, it is biocompatible 
(Figure 56, 63 and 68) and it is able to enter the cells, as demonstrated by confocal 
microscopy (Figure 64 and 69).  
Even if the preliminary data identifies Graphene as a very good candidate for siRNA 
delivery, the siRNA effect still needs to be investigated: silencing experiments and 
consecutive RNA and proteins expression analyses will be performed, as well as the 
investigation of the targeting capability induced by a conjugated antibody.  
Both PVP and RGO nanosystems will be studied also for the Egr-1 or Bcl-2 silencing effects, 
through migration and invasion experiments (transwell migration or invasion assays) or 
enzymatic activation assays of specific proteins involved in the apoptotic pathway. 
All these preliminary data suggest the possibility to develop an innovative therapeutic 
approach for tumour therapy. In particular, Inulin and especially PHEA nanopolymers have 
shown very interesting features with an EPR-mediated passive targeting but also a major 
affinity for the tumour cell membrane. Furthermore, they are able to induce a pH-controlled 
drug release in tumour microenvironment and in the lysosomal compartment. For this 
reason, even their in vivo activity will be investigated. On the other hand, PVP nanogels and 
graphene seem very good candidates as delivery system thanks to their specific properties 
that permit to link siRNA without any degradation effect. PVP NGs present high 
biocompatibility and a GHS-controlled siRNA release; furthermore, precedent studies has 
demonstrated an active tumour targeting antibody-mediated (Adamo, 2013). Finally, 
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graphene data are still very preliminary, but they are promising, thus encouraging further 
studies. 
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